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1. INTRODUCTION 
1.1 Atherosclerosis 
Cardiovascular diseases (CVDs) arising from atherosclerosis are a major clinical 
problem worldwide (1). More and more persons all over the world suffer from diverse 
forms of CVDs, including heart attacks, strokes and angina. For instance, 
approximately 33% of deaths in 2008 in the United States were due to vascular 
diseases (2). 
Atherosclerosis is a chronic inflammatory disorder of arterial blood vessels 
characterized by hardening of the vessel wall and narrowing of the arterial lumen, 
resulting from interactions between diverse cytokines, lipoproteins, blood cells, and 
cellular elements of the arterial wall (3, 4). The multifactorial and multiple-step 
process of atherosclerosis could be categorized into four phases: the initiation phase, 
the stable phase, the vulnerable phase, and the rupture phase (3) (Fig. 1). 
In the initiation phase (Fig. 1A), several physiological and behavioral risk 
factors cause dysfunction of ECs, adhesion of leukocytes and platelets, and increased 
permeability of the vessels (5). In response to a local chemoattractant gradient, 
adherent monocytes migrate into the subendothelial space, where they differentiate 
into macrophages. Cholesterol progressively accumulates in macrophages via the 
uptake of oxLDL by scavenger receptors (e.g., SR-A and CD36) (6). Accumulation of 
cholesterol-laden macrophages (known as foam cells) leads to formation of the 
characteristic fatty streak, which is one of the features of the stable phase (3, 4) (Fig. 
1B). Over time, these fatty streaks progress into complicated lesions containing a 
massive accumulation of lipid and necrotic debris. Meanwhile, smooth muscle cells 
(SMCs) also migrate into the plaque, proliferate, synthesize extracellular matrix 
proteins, and form a fibrous cap that covers the lipid core of the plaques. Additionally, 
activated T cells in the lesion express Th1 and Th2 cytokines, initiating a broad range 
of immune responses. Inflammation and oxLDL cause programmed cell death of 
lesional cells during the development of plaques, which results in the formation of a 
necrotic core. In addition, neovascularization and hemorrhage occur in atherosclerotic 
lesions, which are hallmarks of the vulnerable phase (3, 4) (Fig. 1C). Finally, a 
combination of factors, such as matrix metalloproteinase secretion, extensive fibrin 
deposition, increasing neovascularization, and hemorrhage may result in plaque 
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erosion and rupture, eventually inducing thrombus formation and coagulation via the 
release of pro-thrombogenic plaque material (3, 4, 7) (Fig. 1D).  
 
Figure 1. The development of atherosclerosis (A) Pro-inflammatory stimulation by 
hyperlipidemia causes endothelial-cell dysfunction and activation, the adhesion of 
platelet and leukocytes, and increased permeability of endothelium. (B) Recruited 
monocytes accumulate lipids and differentiate into macrophages (foam cells), which 
constitute fatty streaks. Enhanced mononuclear-cell influx, deposition of matrix 
components, and the accumulation of SMCs are characteristic for the 
fibroproliferative progression of atherosclerotic lesions. (C) SMCs migrate into the 
plaques, proliferate and form a fibrous cap. Apoptosis of mainly plaque macrophages 
gives rise to a necrotic core. Neovascularization and hemorrhage can occur within the 
plaque. (D) Through matrix degradation by proteases and thinning of the fibrous cap, 
unstable plaques ultimately rupture, and elicit the coagulation cascade and thrombosis 
[adapted from Weber C et al. (3) ]. 
1.2 Restenosis 
There are several pharmacological and surgical therapies for symptomatic 
atherosclerotic diseases. Pharmacological management of atherosclerosis consists in 
statin and antiplatelet drug therapy (8). Interventional therapies include surgical 
bypass grafting and the implantation of drug-eluting stents by balloon angioplasty (9, 
10). Restenosis (recurrent stenosis) is a major limitation of these interventional 
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therapies, despite significant technical innovations (11). Restenosis is the renarrowing 
of the target vessel segment following revascularization by excessive neointima 
formation and medial hypertrophy. It is initiated by an inflammatory response to 
mechanical injury and eventually evolves into the hypertrophic wound healing, which 
is predominantly associated with massive macrophage accumulation and SMCs 
proliferation in the neointima (11, 12). 
1.3 The leukocyte adhesion cascade 
The leukocyte adhesion cascade is a crucial biological mechanism involved in various 
physiological and pathological processes (Fig. 2), like the recruitment of leukocytes to 
sites of inflammation (13). This cascade includes 5 main steps: 1) Rolling. Leukocyte 
rolling along the vessel wall under flow conditions depends on the interaction of 
selectins with their ligands (13). Selectins, like endothelial P-selectin and E-selectin, 
bind to P-selectin glycoprotein ligand 1 (PSGL1) or other glycosylated ligands 
expressed on leukocytes, which enables short term interactions of leukocytes with the 
endothelium and triggers intracellular signals (14-17). 2) Arrest. In response to 
inflammation, ECs, platelets, and activated mast cells secrete chemokines and 
chemoattractants, which promote firm arrest of rolling leukocytes by activating 
integrins (13). Integrins are heterodimeric adhesion receptors consisting of a 
membrane-spanning α and β subunit that play an essential role in cell-cell, cell-
matrix, and matrix (extracellular)-cytoskeleton (intracellular) interactions (18, 19). 
Chemokines induce firm arrest of rolling leukocytes by activating mainly β1- (e.g., 
VLA-4) and β2-integrins (e.g., LFA-1 and MAC-1) through GPCR-mediated inside-
out signaling (13, 20), which increases the avidity of integrins towards their ligands, 
such as ICAM-1 and VCAM-1 (13). 3) Adhesion strengthening and spreading. 
Integrin binding induces concurrently outside-in signaling, which is required to 
further enhance adhesion (13). 4) Intravascular crawling. ICAM-1 and MAC-1 play a 
crucial role in leukocyte crawling (21, 22) by which leukocytes find the preferred 
place for transendothelial migration. 5) Transmigration. Transendothelial migration 
(diapedesis) can occur either via a paracellular or transcellular route and is mainly 
mediated by junctional molecules, like PECAM-1 and JAM-A (23-25). This 
leukocyte adhesion cascade has been suggested to provide a basis for novel and 
combinatorial therapies of atherosclerotic diseases (13). 
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Figure 2. The leukocyte adhesion cascade. The original leukocyte adhesion cascade 
includes three steps (shown in bold): selectin-mediated rolling, chemokine-mediated 
activation, and integrin-mediated arrest. This cascade was modified by the discovery 
of additional steps: capture (or tethering), slow rolling, adhesion strengthening and 
spreading, intravascular crawling, and paracellular/transcellular transmigration. The 
chief molecules participating in each step are shown in boxes [adapted from Ley et al. 
(13)] . 
1.4 Monocytes and macrophages in atherosclerosis and neointima 
formation 
Monocytes are a leukocyte subtype that plays a central role in the innate immune 
response, which is essentially involved in multiple steps during atherogenesis (26, 
27). In humans, 10% of blood leukocytes are monocytes. In contrast, only 4% of the 
leukocytes are monocytes in mice (28). Hematopoietic stem cells (HSCs) firstly 
differentiate into common myeloid progenitor cells (MP) and common lymphoid 
progenitor cells (LP) (26). MPs can develop into monocytes, macrophages, and 
dendritic cell precursors (MDPs), which mainly give rise to monocytes and common 
dendritic cell precursors (CDPs) (26).  
Monocyte heterogeneity is well established and human blood monocytes can 
be categorized into three distinct populations based on the surface receptor 
expression: CD14+CD16-, CD14-CD16+ and CD14dimCD16- monocytes (29-31). In 
mice, two subpopulations of blood monocyte, the CD115+Ly6C+ and the 
CD115+Ly6C- monocytes, were functionally characterized by adoptive transfer and 
intravital studies (32, 33).  
Ly6C+ monocytes play a role in proteolysis, phagocytosis, and inflammation, 
and can differentiate into classically activated inflammatory macrophages (M1-type), 
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Tip-DCs (TNF-α/iNOS-producing DCs), and myeloid-derived suppressor cells 
(MDSCs) (26, 27, 34, 35). Under homeostatic conditions, Ly6C- monocytes patrol 
along blood vessels to monitor the endothelium and surrounding tissues (32). In 
response to inflammation, Ly6C- monocytes can differentiate into alternatively 
activated macrophages (M2-type) and alveolar macrophages, participating in 
chemokine expression, phagocytosis, wound repair, and tissue remodeling (26, 27, 
35). 
Monocytes play a key role in the pathogenesis of restenosis and 
atherosclerosis. Circulating monocytes infiltrate injured or inflamed vessels and 
subsequently differentiate into macrophages, which is the most abundant cell type in 
atherosclerotic plaques and neointimal lesions (27). Accordingly, transient depletion 
of peripheral monocytes by liposomal alendronate inhibits neointima formation after 
vascular injury (36). Moreover, atherosclerotic plaques in patients with unstable 
angina or non-Q-wave myocardial infarction contain more macrophages compared to 
patients with stable angina (37). Furthermore, hypercholesterolemia increases the 
Ly6C+ monocyte population in the circulation during atherosclerosis (38). Ly6C+ 
monocytes preferentially infiltrate into atherosclerotic lesions (39, 40) and also play a 
decisive role in the progression of transplant atherosclerosis particularly under 
hyperlipidemic conditions (41). Within atherosclerotic lesions, Ly6C- monocytes tend 
to develop into CD11c+ cells, which contribute to atherosclerosis (40, 42). Following 
myocardial infarction, Ly-6C- monocytes attenuate inflammation and promote 
collagen deposition, angiogenesis, and the accumulation of myofibroblasts (35). 
Altogether, two monocyte subsets with different and complementary functions may 
participate in the progression of restenosis and atherosclerosis.  
Lesional macrophages take up lipid via scavenger receptors and become foam 
cells, which expand the neointima and atherosclerotic plaques (43). Moreover, 
accumulated macrophages also produce a series of cytokines, inflammatory 
mediators, and growth factors, which further modulate the process of neointima 
formation and atherosclerosis through promoting SMC and EC proliferation, 
increasing monocyte recruitment, and enhancing the inflammatory response (44-46). 
Accordingly, monocyte-derived macrophages act as a principal effector cell type in 
the process of restenosis and atherosclerosis.  
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1.5 Chemokines and chemokine receptors  
1.5.1 Chemokines 
Chemokines (short version for chemotactic cytokines) and their heptahelical receptors 
play a critical role in neointimal remodeling and atherosclerotic plaque progression by 
orchestrating leukocyte trafficking (47).  
Chemokines are small-sized proteins (approximately 8 - 10 kDa), which share 
a very similar tertiary structure and can be grouped into four families according to the 
first two of four cysteine residues (CC, XC, CXC, and CX3C chemokines) (Fig. 3) 
(48). CXC chemokines are further subdivided into two groups depending on the 
presence of a Glu-Leu-Arg motif (the ELR) immediately preceding the first cysteine 
residue. ELR+ CXC chemokines are proangiogenic, whereas ELR- CXC chemokines, 
except CXCL12, are angiostatic (49, 50). Chemokines are usually secreted, but 
membrane-anchored chemokines, such as CX3CL1 and CXCL16, have been 
described (51, 52).  
 
Figure 3. Chemokines and their receptors. A single chemokine (CC, blue; CXC, 
green) generally binds multiple receptors and one receptor usually can bind more than 
one chemokine. Decoy receptors (black) engage various chemokines, but do not 
induce intracellular signaling. However, a minority of chemokine (red)-chemokine 
receptor interactions are monogamous [adapted from Sun et al. (53)].  
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1.5.2 Chemokine receptors 
GPCRs are a superfamily of cell surface signaling proteins (54). These receptors play 
a pivotal role in various physiological functions and diseases, and are therefore 
common drug targets (55). Usually, chemokines promiscuously bind to one or more 
of approximately 23 GPCRs, thus inducing heterogeneous biological functions. 
Chemokine-induced receptor activation triggers downstream signaling by coupled G 
proteins. However, 3 non-signaling (decoy) receptors exist, which bind to a number of 
different chemokines. According to the chemokines that bind to the receptor, 
chemokine receptors are divided into four groups (i.e., CC receptors, XC receptors, 
CXC receptors, and CX3C receptors) (56). 
Chemokine receptors are structurally characterized by seven membrane-
spanning domains with an extracellular N-terminus, an intracellular C-terminus, 3 
intracellular (ICLs), and 3 extracellular loops (ECLs) (57). The conserved amino acid 
sequence Asp-Arg-Tyr (DRY motif) in the 2nd ICL is responsible for signal 
transduction (58, 59). Surprisingly, CXCR4-mediated activation of Gi does not 
require the DRY motif (60).  
Like most GPCRs, chemokine receptors can exist in oligomeric complexes, 
including dimers (homodimers/ heterodimers) and higher-order oligomers (61, 62). 
Most oligomerizations are constitutive rather than ligand-dependent (63). GPCR 
oligomerization plays a crucial role in ligand binding, G protein activation, and signal 
transduction (56, 61). 
1.5.3 CXCL12 and CXCR4 
The CXCL12/CXCR4 axis has been implicated in the vascularization, progenitor cell 
trafficking, lymphocyte migration, HIV-1 entry, tumor growth, and metastasis (64-
72). CXCL12, also known as pre–B cell growth stimulating factor (PBSF) or stromal-
derived factor (SDF-1), is a CXC chemokine that is ubiquitously expressed in 
vertebrate tissues (73-75). The CXCL12 cDNA is highly conserved during evolution 
and encodes two splicing variants, CXCL12α (89 residues) and CXCL12β (93 
residues), the C-terminal of the latter contains 4 additional amino acids (76).  
The high expression of CXCL12 in osteoblasts, stromal cells, and ECs within 
the bone marrow generates a concentration gradient between the bone marrow and 
peripheral blood, which retains HSCs in the bone marrow (77, 78). Disturbance of this 
CXCL12 gradient by either a decrease of CXCL12 in the bone marrow or an increase 
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of CXCL12 in the peripheral blood can induce the migration of HSCs into the blood 
circulation (79-81). 
Since Cxcl12-/- mice display numerous similar phenotypes as Cxcr4-/- mice, 
including defective hematopoiesis, ventricular septum defect, abnormal cerebellum, 
and prenatal lethality, CXCL12 and CXCR4 have been regarded as an exclusive 
ligand-receptor pair (82, 83). Accordingly, the effects of CXCL12 have been 
attributed to its interaction with CXCR4. The CXCL12/CXCR4 axis has been 
intensively studied in vascular repair after mechanical injury and atherosclerotic 
lesion formation (84-89). 
1.5.3.1 The role of CXCL12 in atherosclerosis 
Bone marrow-derived CXCL12 appears to be beneficial in atherosclerosis, because 
mice in which CXCR4 is inhibited in the bone marrow develop increased 
atherosclerosis by releasing neutrophils into the circulation (86, 90). Moreover, up-
regulation of CXCL12 in atherosclerotic lesion by microparticle-mediated delivery of 
miR-126 from apoptotic ECs is atheroprotective, probably due to the recruitment of 
circulating angiogenic cells (91). High plasma CXCL12 concentrations are associated 
with increased plaque stability most likely due to anti-inflammatory and matrix-
stabilizing effects of CXCL12 (92). Plasma CXCL12 levels are decreased in patients 
with ST-elevation myocardial infarction (STEMI), indicating that CXCL12 maybe 
protective in patients with acute myocardial infarction (93). 
However, CXCL12 may also exert pro-atherogenic effects, because the 
abundant CXCL12 expression in the atherosclerotic plaque by macrophages, SMCs, 
and ECs can trigger platelet aggregation via interaction with CXCR4, which may 
accelerate the development of atherosclerosis (94). Additionally, genome-wide 
association studies (GWAS) identified a coronary artery disease risk allele (10q11) 
downstream of the CXCL12 gene, which is associated with elevated plasma CXCL12 
levels (95). During vascular repair, interruption of the CXCL12/CXCR4 interaction 
by a Cxcl12 antibody, small molecule Cxcr4 antagonists, or transplantation of Cxcr4-/- 
bone marrow cells diminishes neointimal hyperplasia due to reduced recruitment of 
smooth muscle progenitor cells (SPCs) (84, 85, 87, 89). Accordingly, CXCL12 
appears to participate in the progression of vascular remodeling and atherosclerosis in 
a context-dependent manner.  
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1.5.3.2 The role of the CXCL12/CXCR4 axis in vascular repair by SPCs  
During neointima formation, contractile medial SMCs transform into synthetic SMCs, 
which migrate into the intima, proliferate, and produce extracellular matrix (96-99). 
This paradigm has been complemented by ample evidence indicating that HSCs and 
resident stem cells can be recruited to the intimal layer of injured vessels and give rise 
to intimal SMCs (84, 100, 101). Controversial results exist on the origin of SPCs and 
the extent of their participation in neointima formation and atherosclerosis, which 
might be due to the different models used (vascular injury versus graft or diet-induced 
atherosclerosis), varying staining procedures (like the marker used to define SMCs) 
and microscope techniques, or the mouse strains (102, 103).  
Despite these controversies, it is clear that peripheral blood progenitor cells 
(PBPCs) contribute much more to neointima formation after mechanical vascular 
injury than to atherosclerotic plaque formation. PBPCs that express the stem cell 
antigen (Sca-1+) but no hematopoietic lineage markers (Lin-) are increased in the 
circulation after vascular injury, and can be detected in the neointima where they 
express SMC markers, such as SMMHC (84). These data concur with the results from 
Simple et al., who reported that bone marrow-derived mononuclear cells (BMMCs) 
differentiate into SMC-like cells in vitro after treatment with platelet-derived growth 
factor-BB (PDGF-BB) (104). Furthermore, Sata et al. found in mice, which express 
the reporter gene lacZ in bone marrow cells that more than half of all neointimal and 
medial cells originate from the bone marrow. These lacZ+ cells express SMCs 
markers, such as α-SMA, suggesting that neointimal SMCs could be derived from the 
bone marrow (100). Similar results are obtained in a parabiotic model, which avoids 
unexpected effects of irradiation (105). Furthermore, bone marrow-derived SMCs 
expressing lacZ under the control of the SMC-specific promoter SM22 can be 
detected in the neointima of mice by two-photon laser scanning microscopy 
(TPLSM), confirming that circulating SPCs differentiate into neointimal SMC cells 
(106). TPLSM provides 3D-dimensional fluorescent images of viable arteries at a 
single-cell resolution avoiding false-positive signals from adjacent cells and fixation 
artifacts. Additionally, bone marrow-derived smooth muscle-like cells promote 
atherosclerosis by secreting proinflammatory cytokines and mitogens (107). In 
summary, SPCs are mobilized from the bone marrow into the blood after mechanical 
vascular injury and are recruited into neointimal lesions, thus contributing to 
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neointimal hyperplasia. Remaining questions regarding the definition of SPCs and of 
differentiated SMCs, the origin of SPCs, and the potential contribution of SPCs under 
specific conditions need to be further addressed.  
The interaction of CXCR12 and CXCR4 maintains hematopoietic progenitor 
and stem cells within the bone marrow niches under homeostatic conditions and the 
disruption of the CXCL12 gradient leads to the mobilization of stem cells to the 
peripheral circulation (Fig. 4) (79, 80, 108). Following vascular injury, the apoptotic 
medial SMCs secrete apoptotic bodies, which induce the expression of CXCL12 in 
uninjured SMCs (84, 85). Moreover, activated platelets not only secrete CXCL12, but 
also present CXCL12 at the site of injury (85, 109). Plasma CXCL12 levels are 
elevated at 1 d and return back to baseline levels at 2 wks after injury (85). However, 
the expression of CXCL12 in the injured arteries is abundant throughout neointima 
formation (84). Elevated CXCL12 levels in the circulation disturb the gradient of 
CXCL12 between bone marrow and peripheral circulation, and consequently mobilize 
CXCR4+ SPCs, which contribute to neointimal hyperplasia (84, 85). Neointima 
formation is ameliorated by treatment with a CXCL12 antibody or a CXCR4 
antagonist, confirming the critical role of the CXCL12/CXCR4 axis (85, 87, 95). 
Understanding the exact mechanism of SMCs recruitment in vascular diseases will 
pave the way for novel preventive and therapeutic strategies against restenosis (96). 
 
 
 
Figure 4. The CXCL12/CXCR4 axis recruits SPCs during vascular repair. 
Medial and neointimal SMCs produce CXCL12, which is released into the circulation 
and thus alters the CXCL12 gradient between the bone marrow and circulation. The 
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disrupted CXCL12 gradient results in the mobilization of SPCs, which are 
subsequently recruited to injury site via CXCL12 bound on the platelet surface 
[adapted from Schober et al. (108)]. 
 
1.5.4 CXCR7 
CXCR7 (formerly known as RDC1) is an alternative receptor for CXCL12, 
which additionally binds to CXCL11 (110, 111). Two research groups independently 
reported a high rate of postnatal death and dilated ventricles in Cxcr7-/- mice (112, 
113). Sierro et al. also detected thickened cardiac valve leaflets due to chondrification 
in Cxcr7-/- mice (113). In contrast to Cxcl12-/- and Cxcr4-/- mice, hematopoiesis is not 
impaired in Cxcr7-/- mice (113). Furthermore, endothelial cell-specific deletion of 
Cxcr7 recapitulated the phenotype of mice with a ubiquitous Cxcr7 deletion (112, 
113). Although the majority of Cxcr7-/- mice develop dilated right ventricles in the 
study by Sierro et al. (113), Gerrits et al. found dilatation of both ventricles and 
cardiomyocyte hyperplasia in some Cxcr7-/- mice (112).  
CXCR7 mRNA is ubiquitously expressed in diverse tissues and cell types and 
promoter activity of the Cxcr7 gene is detectable in the cardiovascular and nervous 
system as well as in the bones (112). CXCR7 protein is expressed on the surface of 
various malignant cell types, haematopoietic cells, and activated ECs, but not on 
leukocytes (110, 114-118). Moreover, CXCR7 expression is directly repressed by 
hypermethylated in cancer 1 (HIC1) in U2OS cells (119) and is downregulated by 
estrogens (E2) in breast cancer cells (120). In HUVECs, stimulation with pro-
inflammatory cytokines, such as TNF-α and interleukin-1β (IL-1β), or hypoxic 
conditions increase CXCR7 mRNA expression (110, 121, 122). Furthermore, CXCR7 
expression is upregulated by activated NF-κB in tumor cells, such as Jurkat cells and 
rhabdomyosarcomas (116, 118, 123). 
Ligand binding to CXCR7 affects cell adhesion, cell proliferation and 
survival, and leukocyte infiltration (110, 113, 124). However, CXCR7 activation fails 
to induce heterotrimeric Gαi protein activation and subsequent intracellular calcium 
mobilization (110), although it shows homology with conserved domains of GPCRs 
and may constitutively interact with G proteins (125, 126). One possible explanation 
is that CXCR7 contains a DRYLSIT-sequence instead of the conserved DRYLAIV 
domain, which is coupling to G proteins (127, 128). However, replacement of the 
DRYLSIT motif of CXCR7 with DRYLAIV does not result in chemotaxis and 
INTRODUCTION 
 
12 
 
calcium mobilization upon stimulation with CXCL12 (128). Additionally, CXCR7 
forms heterodimers with CXCR4, which can either activate or inhibit the signaling of 
CXCR4 (113, 126). Co-expression of CXCR7 and CXCR4 reduces CXCR4-mediated 
calcium response in HEK-293T cells by altering conformational rearrangement 
between CXCR4 and G proteins (126). In contrast, a potentiated calcium response is 
induced in HEK293 cells expressing both CXCR7 and CXCR4 (113). The 
intracellular crosstalk of CXCR7 and CXCR4 enhances rapid integrin activation 
induced by CXCL12 (129). Moreover, CXCR7 mediates the recruitment of β-
arrestins leading to MAP kinases activation (130). This β-arrestin-linked signaling 
pathway is promoted by CXCR7/CXCR4 heterodimers compared to the signaling by 
G protein coupling (131). Furthermore, CXCR7 has important functions as a non-
signaling decoy receptor that continuously scavenges and degrades its ligands through 
internalization (128, 132). This scavenging function of CXCR7 shapes the 
extracellular gradients of its ligands, such as CXCL12, and thus modulates the effects 
of CXCL12 in mammalian cells and zebrafish (128, 132). Taken together, CXCR7 
may play a key role in the modulation of CXCL12/CXCR4 axis. 
CCX771 is a small molecule with high affinity and selectivity for CXCR7, and 
it competes with CXCL12 and CXCL11 for the binding to CXCR7 (110, 124). 
However, CCX771 does not only antagonize the binding of CXCL12 and CXCL11 to 
CXCR7, but induces β-arrestin recruitment to CXCR7 more strongly than the 
endogenous CXCR7 ligands (133).  
1.6 Aims of the study 
Chemokines and their receptors govern atherosclerosis and vascular remodeling by a 
complex and fine-tuning network (1, 47). Compelling evidence demonstrated that the 
CXCL12/CXCR4 axis is essentially involved in restenosis and atherosclerosis by 
modulating SPC mobilization and neutrophils homeostasis, respectively; however, 
relatively little is known about the role of CXCR7 in these processes (84, 85, 108). 
This study tests the hypothesis that CXCR7 modulates the effect of the 
CXCL12/CXCR4 axis in vascular repair and atherosclerosis. 
Widespread Cxcr7 expression has been previously reported (112, 129, 134, 
135), but little is known is about the expression of Cxcr7 in the arteries during 
atherosclerotic diseases. Therefore, the first aim of this study was to determine the 
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transcriptional and translational expression pattern of Cxcr7 in Apoe-/- mice during 
atherosclerosis and neointima formation.  
Secondly, this study aimed to identify the role of Cxcr7 on neointima 
formation after vascular injury, on the mobilization of SPCs, and on the alteration of 
Cxcl12 levels in Apoe-/- mice with an inducible Cxcr7 knockout. 
The third aim of the study was to assess the effects of the synthetic CXCR7-
ligand CCX771 on neointima formation after vascular injury, the mobilization of 
SPCs, and the alteration of Cxcl12 levels. Moreover, the role of CCX771 in diet-
induced atherosclerosis was examined. 
Finally, the mechanism of the effect of Cxcr7 and CCX771 on neointima 
formation and atherosclerosis was studied. 
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2. MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Equipment 
Table1: List of general laboratory equipment 
Equipment                                                       Company 
7900HT Fast Real-Time PCR 
System 
Applied Biosystems, Darmstadt, Germany 
Aladdin-1000 World Precision Instruments, Inc.USA 
Balance Sartorius, Göttingen, Germany 
Biosprint 15 system Qiagen, Hilden, Germany 
CCD camera JVC, USA 
CO2-Incubator HERA cell 240 Fisher Scientific GmbH, Schwerte, Germany 
CUT 6062 SLEE MAINZ, Germany 
DNA engine opticon Bio-Rad laboratories GmbH, Munich Germany 
GenoPlex  system VWR International, LLC, Germany 
Eppendorf 5417C Eppendorf, Hamburg, Germany 
FACSCantoTM II BD Biosciences, San Jose, CA, USA 
Hematology analyzer MEK-6450K Nihon Kohden, Rosbach v.d.H., Germany 
Heraeus Labofuge 400 Heraeus, Osterode,Germany 
Heraeus Multifuge 3 S-R Heraeus, Osterode,Germany 
Infinite M200  Tecan, Crailsheim, Germany 
Laminar flow hood  Heraeus, Osterode, Germany 
Leica CM3050 S  cryostats Leica, Wetzlar, Germany 
Leica DM 2500 Leica, Wetzlar, Germany 
Leica DMLB  Leica, Wetzlar, Germany 
Leica EG 1160 Leica, Wetzlar, Germany 
Milli Q Millipore, Schwalbach, Germany 
Mini-sub cell GT  Bio-Rad, Hercules, USA 
MyCycler  Bio-Rad, Hercules,USA  
NanoDrop  Peqlab, Erlangen, Germany 
Olympus BX61WI  Olympus Optical, Hamburg,Germany 
Olympus CK30-F200 Olympus Optical, Hamburg,Germany 
Olympus CK31RBSF Olympus Optical, Hamburg,Germany 
Olympus SZX10 Olympus Optical, Hamburg,Germany 
Opticon Real-Time PCR System Bio-Rad Laboratories GmbH, Munich, 
Germany 
pH meter InoLab level 1  WTW, Weilheim, Germany 
Systec 2540EL Systec, Wettenberg, Germany 
Tissuelyser LT Qiagen, Germany 
 
                                                                                                      MATERIALS AND METHODS 
 
15 
 
2.1.2 Assay kits 
Table 2: Assay kits 
Kit Company 
BioSprint 15 DNA Blood Kit Qiagen, Germany 
Cell Lysis Buffer (10×) Cell signaling, MA, USA 
Cholesterol assay kit Cayman Europe, Germany 
DC Protein Assay Kit Bio-Rad, USA 
DiI-VLDL Kalen Biomedical, USA 
Elastic van Gieson kit Merck, Germany 
GAPDH primer set Qiagen, Germany 
ImaGene Green C12 FDG lacZ Gene 
Expression Kit 
Invitrogen, Karlsruhe, Germany 
Mouse Cxcl12 Elisa kit Ray biotech, Inc., GA, USA 
Murine Cxcr4 primer set Qiagen, Germany 
Murine Cxcr7 primer set Qiagen, Germany 
Murine Ldlr primer set Qiagen, Germany 
Murine rpl13a  primer set Qiagen, Germany 
Murine Vldlr primer set Sigma-Aldrich, Munich, Germany 
Murine β-actin primer set Qiagen, Germany 
Qproteome Mammalian Protein Prep Kit Qiagen, Germany 
Quantitect SYBR green PCR kit Qiagen, Germany 
Quick-Load 100 bp DNA Ladder Biolabs, USA 
Reverse Transcription M-MLV Reverse 
Transcriptase 
Promega, Madison, USA 
RNA isolation RNeasy Mini/Micro Kit  Qiagen, Hilden, Germany 
SYBR Green qPCR Master Mix  Fermentas, St. Leon-Rot, Germany 
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2.1.3 Buffers and solutions 
Table 3: List of buffers and solutions 
Buffer/Solution Composition 
Agarose gel 2 g agarose, 6 µl ethidium bromide, 100 ml 1× TBE. 
Anesthesia solution 0.1 ml of ketamine hydrochloride (80 mg/kg), 0.05 ml of 
xylazine (5 mg/kg), and 0.85 ml of 0.9% sodium chloride. 
Tamoxifen solution Tamoxifen (Sigma-Aldrich, USA) was dissolved in neutral 
oil at the concentration of 15 mg/ml or 20mg/ml. 
FACS staining buffer 1.6% mouse serum; 1.6% rabbit serum; 1.6% human 
serum; 1.6% bovine serum albumin (BSA); dissolved in 
PBS. 
Hank´s complete 
solution 
1× HBSS, 0.3 mM EDTA, 0.1% BSA. 
HBSS 1× solution 1:10 diluted 10× HBSS (Calcium, Magnesium). 
Blocking solution PBS containing 1% BSA and 2.5% blocking serum, or 
PBS containing 10% blocking serum (option: 0.2% Triton 
X-100 for permeabilization). 
Paraformaldehyde 4% paraformaldehyde dissolved in PBS, pH 7.4 - 8. 
Primary antibody buffer PBS containing 10% blocking solution 
Red blood cell lysis 
buffer 
150 mM NH4Cl; 10 mM KHCO3; 0.1 mM EDTA, pH 7.4 
Sodium Citrate Cooking 
Buffer  
12.6 ml of 0.1 M citric acid; 57.4 ml of 0.1 M NaCitrate 
dehydrate; 0.35 ml Tween20, and 630 ml distilled water. 
(Ajust pH to 6.0 with 5 M NaOH).  
X-gal washing solution PBS containing 2 mM MgCL2. 
X-gal staining solution 5 mM potassium ferrocynide, 5 mM potassium 
ferricyanide, 2 mM MgCl2, 0.02% Nonidet P-40 (was 
diluted from 10% stock), 0.01% Na deoxycholate (diluted 
from 10% stock), and 1 mg/ml X-gal (was dissolved 
invdimethylformamide, Invitrogen), were dissolved in 
PBS. 
X-gal stock solution 40 mg/ml X-gal in dimethylformamide (store at -20°C in 
foil covered glass contain). 
Vitro-Clud mounting 
medium 
Vitro-Clud (Angenbrinck, Emmendingen, Germany) 
diluted into xylene. 
1% Alcian blue solution 1 g Alcian blue (Sigma A5268), 100 ml milipore water, 
and 1 ml acetic acid (filtration). 
Alkaline ethanol 5 ml ammonium hydroxide was mixed with 95 ml of 96% 
ethanol. 
Orcein-Verhoeffschem 
Hematoxylin solution A 
1 g Orcein (Merck, 1071000025), 98 ml 70% ethanol, 1 ml 
25% HCL (filtration). 
Orcein-Verhoeffschem 
Hematoxylin solution B 
8 g Hematoxylin (Sigma, H3136), 160 ml 100% ethanol. 
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Buffer/Solution                Composition 
Orcein-Verhoeffschem 
Hematoxylin solution C 
9.6 g Iron(III)-Chloride (Merck, 8039450500), 90 ml 
Millipore water. 
Orcein-Verhoeffschem 
Hematoxylin solution D 
1 g Iodine, 2 g Potassium iodide, and 97 ml Millipore 
water. 
Orcein-Verhoeffschem 
Hematoxylin working 
solution 
25 ml of Orcein-Verhoeffschem Hematoxylin solution A;           
20 ml of Orcein-Verhoeffschem Hematoxylin solution B;           
8 ml of Orcein-Verhoeffschem Hematoxylin solution C;             
8 ml of Orcein-Verhoeffschem Hematoxylin solution D.  
Acidic alcohol 1 ml of 25% HCL and 100 ml of 95% ethanol. 
Brilliant Crocein Scarlet 
MOO solution A 
0.1 g Brilliant Crocein Scarlet, 0.5 ml Acetic acid, and 
99.5 ml Millipore water. 
Brilliant Crocein Scarlet 
MOO solution B 
0.1 g Acid fuchsin (Merck, 105231), 0.5 ml Acetic acid, 
and 99.5 ml Millipore water. 
Brilliant Crocein Scarlet 
MOO working solution 
40 ml Brilliant Crocein Scarlet MOO solution A and 10 
ml Brilliant Crocein Scarlet MOO solution B. 
0.5% acetic acid 1 ml of acetic acid and 200 ml of milipore water. 
6% alcoholic saffron 6 g of saffron was dissolved in 94 ml of absolute ethanol 
and stored at 56 ºC for 48 hours before use. 
Oil red O stock 1 g oil red O (Sigma-Aldrich, St. Louis, USA) in 200 ml 
99% isopropanol. 
Oil red O working 
solution 
Dilute Oil red O stock with distilled water in a ration 3:2, 
stand for 1 h and through filter paper. 
Glycerine mounting 
Medium 
10 g gelatin, 70 ml glycerol, 0.25 g phenol in 60 ml 
distilled water. 
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2.1.4 Consumables 
Table 4: Consumables 
Consumables Company 
96-well plates Nunc, Denmark 
EDTA-coated tubes Sarstedt, Germany 
FACS-tubes BD Biosciences, USA 
Microhematocrit capillary tube Hilgenberg, Germany 
SuperFrost® Plus slides  Thermo Scientific, Germany 
Polysine™ slides Thermo Scientific, Germany 
PAXgene tissue containers Qiagen, Germany 
QIAshredder homogenizer Qiagen, Germany 
SERAFLEX suture (USP 5/0, EP 0.5) SERAG WIESSNER, Germany 
SERAFLEX suture (USP 7/0, EP 1) SERAG WIESSNER, Germany 
Serological pipettes (5 ml, 10 ml, 25 ml)  Corning, USA 
Serum-separating tubes Sarstedt, Germany 
Sterile filter-tips  Starlab, Germany 
Superose 6 10/300 colum GE healthcare, USA 
Syringes (2 ml, 5 ml, 10 ml, 20 ml)  Terumo, Belgium 
2.1.5 Chemicals, reagents, and cell culture medium 
Table 5: Chemicals, reagents, and cell culture medium 
Chemical, reagents, medium Company 
Bovine serum albumin Serva, Heidelberg, Germany 
Collagen Type I, Rat Tail Millipore,USA 
Collagenase Type II Invitrogen,Germany 
cOmplete, Mini Protease Inhibitor  Roche, Swiss 
DiI-VLDL  Kalen Biomedical, Montgomery Village, USA 
Endothelial cell growth medium Promocell,Germany 
Gibco® HBSS (10×) Life Technologies, Inc., USA 
Gibco® HBSS (10×, Calcium, 
Magnesium) 
Life Technologies, Inc., USA 
Human serum Sigma-Aldrich, St. Louis, USA 
IL-1β Pepro Tech, USA 
Isofluran Abbott, Germany 
MIGLYOL® 812 Germany GmbH, Hamburg, Germany 
Mouse serum Sigma-Aldrich, St. Louis, USA 
Nuclear Fast Red  Vector Laboratories Inc., Burlingame, CA, USA 
Rabbit serum Innovative Research, Research, Novi, USA 
Tissue-Tek® O.C.T. compound  Sakura Finetek Germany GmbH, Staufen, 
Germany 
TNF-α Pepro Tech, USA 
Mounting medium with DAPI Vector Laboratories Inc., Burlingame, CA, USA 
X-gal Invitrogen,USA 
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2.2 Methods 
2.2.1 Animal experiments 
2.2.1.1 Animals 
Cxcr7lacZ/+ (136) and Cxcr7flox mice (manuscript in preparation) were generated by 
ChemoCentryx, Inc. CAG-CreERTM (137) and Apoe-/- mice were obtained from The 
Jackson Laboratory (Bar Harbor, Maine, USA). VE-Cad-CreT2 mice were kindly 
provided by Dr. Iruela-Arispe (UCLA, Los Angeles, USA) (138). CAG-CreERTM 
mice were crossed with Cxcr7flox mice to generate CAG-CreERTMCxcr7floxApoe+/+ 
mice, then Apoe-/- mice with a ubiquitous TMX-inducible Cxcr7 knockout (CAG-
Cre+Cxcr7floxApoe-/-) were generated by breeding CAG-CreERTMCxcr7floxApoe+/+ and 
Apoe-/-mice. Additionally, VE-Cad-CreT2 mice were crossed with Cxcr7flox mice to 
generate VE-Cadh-Cre+Cxcr7floxApoe+/+ mice. To generate Apoe-/- mice with an 
endothelial TMX-inducible Cxcr7 knockout VE-Cad-Cre+Cxcr7floxApoe+/+ were 
crossed with Cxcr7floxApoe-/- mice. 
In CAG-Cre+Cxcr7floxApoe-/- mice, Cre recombinase is fused to a mutated 
ligand-binding domain of the murine estrogen receptor (Cre-ERTM), which does not 
bind to its natural ligands, but binds to TMX. Upon TMX binding, Cre-ERTM 
translocates into the nucleus and initiates the recombination of loxP-flanked genes, 
like the Cxcr7flox gene. A chicken β-actin promoter and cytomegalovirus enhancer 
drive the expression of the Cre-ERTM fusion protein (137).  
In VE-Cad-Cre+Cxcr7floxApoe-/-mice, Cre-ERTM expression is under the control 
of the vascular endothelial cadherin promoter (138). Accordingly, TMX-induced Cre-
recombinase mediates the recombination of floxed genes in ECs.  
Of note, the background of mice used in this project is C57BL/6, which 
contains a natural null mutant of Cxcl11, excluding the involvement of Cxcl11 in the 
Cxcr7-mediated signal pathways (113).  
All animal experiments were reviewed and approved by the local authorities 
(LANUV NRW) in accordance with the German animal protection laws. 
2.2.1.2 Wire-induced injury of carotid arteries 
In the wire injury model, mechanically-induced endothelial denudation simulates 
restenosis after angioplasty without disturbing normal blood flow (102, 139). Apoe-/- 
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mice are characterized by severe hypercholesterolemia and a compromised immune 
response. These mice develop enhanced neointimal hyperplasia following vascular 
injury and are susceptible to diet-induced atherosclerosis (102, 140). Therefore, Apoe-
/-
 mice may provide a model for neointima formation that is more closely related to 
clinical restenosis, because in patients the already atherosclerotic artery is 
mechanically injured by the stent implantation or angioplasty. 
Wire injury was performed in Apoe-/- mice after 1 wk of HCD feeding (HCD; 
21% fat and 0.15% cholesterol; Altromin, Lage, Germany) (84). Mice were 
anesthetized with ketamine (100 mg/kg) and xylazin (10 mg/kg) via intraperitoneal 
injection (IP) and then fixed backside down on the operating table. The operating area 
was shaved and swabbed with 70% isopropanol. A skin incision was made at the left 
lateral side of neck, and then the common carotid artery (CCA) and the bifurcation 
area were exposed using a dissecting microscope. Ligatures were placed around the 
proximal part of the CCA, the external carotid artery (ECA), and the internal carotid 
artery (ICA). The distal ligature around ECA was tied off while the ligatures around 
CCA and ICA were pulled and fixed on the operating table, thus suspending blood 
flow locally in the artery. A transverse incision was made in the ECA between the 
proximal and distal ligatures using fine scissors. A 0.36-mm flexible angioplasty 
guidewire was introduced into the arterial lumen through the incision and passed 
through the CCA with rolling movement, thus achieving endothelial denudation. The 
proximal ligature of ECA was permanently ligated following withdrawal of the wire. 
The ligatures of the ICA and CCA were removed and blood flow re-established. Skin 
incisions were closed with clips. 
2.2.1.3 Diet-induced atherosclerosis model 
The diet-induced atherosclerosis model is a commonly used method to aggravate the 
development of atherosclerosis in mice by feeding a diet with high cholesterol content 
(141). Animals were fed a HCD for 3 months until sacrifice.  
2.2.1.4 Splenectomy 
In anesthetized Apoe-/- mice, the left hypochondrium was surgically opened. Then, the 
spleen was dissected from adjacent tissues and removed after the ligation of the 
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vessels of the spleen (142). Wire injury of the carotid artery was performed in these 
mice 2 wks after the splenectomy. 
2.2.1.5 Bone marrow transplantation 
Bone marrow cells were harvested from femurs of CAG-Cre+Cxcr7floxApoe-/- or CAG-
Cre-Cxcr7floxApoe-/- and delivered (4 × 106/mouse) into irradiated recipient Apoe-/- 
mice (2 × 6 Gray, 4 h interval, Faxitron’s CP160) via tail vein injection. Three wks 
later, the recipient Apoe-/- mice were treated with TMX for 5 consecutive days. One 
wk after the final TMX injection, the mice were fed a HCD for 1 wk before wire 
injury of the carotid artery was performed. Tissues and blood were harvested 4 wks 
after vascular injury. 
2.2.1.6 Sacrifice, blood collection, and tissue fixation 
Mice were sacrificed by injection of an overdose of ketamine and xylazine (250 mg 
/kg Ketamine with Xylazine 25 mg/kg administered, IP). Whole blood was collected 
from mice by cardiac puncture and further processed to plasma and serum samples 
(Table 6). In some mice, blood was obtained by puncturing the retro-orbital sinus with 
microhematocrit capillary tubes during short-time anesthesia using isofluran 
inhalation.  
To assess the plasma concentration of CCX771, blood samples were obtained 
1 h and 12 h after a subcutaneous injection of CCX771 (2 mg/ml, dissolved in 10% 
Captisol; 100 µl/mouse). The plasma concentrations of CCX771 were measured using 
liquid chromatography–mass spectrometry (LC-MS) by ChemoCentryx, Inc.  
Table 6: Blood collection 
Samples Tubes Treatment Centrifuge 
Serum Serum-separating 
tubes 
Satisfactory clot retraction for 
at least 30 min 
2000g, 15 min, 4ºC 
Plasma EDTA-coated tubes Mix thoroughly, centrifuge as 
soon as possible 
1000g, 10 min, 4ºC 
For perfusion fixation, a catheter was inserted into the apex of the left ventricle 
and the right atrium was cut to allow outflow of PBS and the fixation solution. Then, 
the circulatory system was flushed with pre-cooled PBS (5 ml) and subsequently 
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perfusion fixation was performed with 4% paraformaldehyde (PFA, 5 ml) using a 
roller pump (1 ml/min, Aladdin-1000). Some mice were fixed by PAXgene Tissue Fix 
(PAXgene Tissue Containers, 500 µl) using a syringe (2 ml) equipped with a 23G 
needle after completing PBS perfusion. 
After incubated in 10% formalin or PAXgene Tissue Stabilizer overnight at 
4ºC, tissues were embedded in paraffin (Leica EG1160) after dehydration (Tissue 
processors). Sections were made by a microtome (CUT 6062). For cryosections, 
tissues were embedded into OCT solution, transferred to liquid nitrogen, and stored at 
-80°C. Sections were made using a cryotome (Leica CM3050 S).  
2.2.1.7 Blood biochemistry 
Serum samples were analyzed by dry chemistry using a Vitros 250 Analyzer to 
determine the total cholesterol, creatinine, alanine transaminase (ALT), or aspartate 
transaminase (AST) levels. Increased levels of AST or ALT indicate hepatic injury. 
Elevated creatinine levels indicate impaired kidney function (143). The EDTA-
anticoagulated blood was analyzed by a hematology analyzer (MEK-6450K). The 
percentage of the leukocyte subtypes was determined by a blood smear. 
Plasma lipoprotein fractions (VLDL, LDL, and HDL) were separated using fast 
protein liquid chromatography (FPLC) by size (144). A Superose 6 10/300GL column 
was first equilibrated with PBS. After loading 200 µl diluted blood plasma solution 
(1:1 diluted in PBS) to a 100-µl injection loop, the system was running with PBS as a 
running buffer at a constant flow rate of 0.5 ml/min. Fractions containing the plasma 
lipoproteins (0.25 mL) were collected and cholesterol was further measured in the 
different fractions using a cholesterol fluorometric assay (Table 2).  
2.2.1.8 CCX771 and tamoxifen administration 
Treatment with CCX771 was performed by daily subcutaneous injections [5 ml/kg of 
CCX771 (2 mg/ml) dissolved in 10% Captisol]. In the control group, mice were 
injected with vehicle alone (5 ml/kg, 10% Captisol, s.c.). Injections were started 1 h 
before injury and continued for 4 wks after vascular injury. In the diet-induced 
atherosclerosis model, the CCX771 treatment was performed daily for 3 months. 
TMX was dissolved in neutral oil (MIGLYOL® 812) at a concentration of 15 
mg/ml or 20 mg/ml. TMX (75 mg/kg, body weight) was injected intraperitoneally for 
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5 consecutive days in CAG-Cre+ Cxcr7floxApoe-/- and CAG-Cre- Cxcr7floxApoe-/- mice. 
TMX (100 mg/kg, body weight) was injected intraperitoneally for 5 consecutive days 
in VE-Cad-Cre+Cxcr7floxApoe-/- and VE-Cad-Cre+Cxcr7+/+Apoe-/- mice. HCD feeding 
was started 7 d and arterial injury was performed 14 d after the last injection of TMX 
(137).  
2.2.2 Molecular biology techniques 
2.2.2.1 Isolation and quantification of DNA and RNA 
The BioSprint 15 DNA Blood Kit was used to purify DNA from murine tails. These 
tails were digested by proteinase K (more than 4 h, 56°C) and the lysates mixed with 
buffer AL (lysis), isopropanol, and Magattract Suspension G were transferred to the 
first well of 5-tube trip. Buffer AW1 (washing), AW2 (washing) and AE (elution) 
were separately added to the other wells. DNA was harvested after running the 
protocol “BS15 DNA Tissue” in the BioSprint 15 workstation. 
Total RNA was extracted using RNeasy micro or mini kit (Qiagen) dependent 
on the weight of tissues or the number of cells. Tissues were lysed and homogenized 
by Tissuelyser LT, and cells by QIAshredder homogenizer. The RNA was isolated 
using RNeasy/RNeasy MinElute spin columns. 
DNA/RNA concentrations were measured using a spectrophotometer 
(NanoDrop). The purity of DNA/RNA was determined by the ratio of the absorbance 
at 260 nm and 280 nm. DNA and RNA with an approx. Ratio260/280 of 1.8 and 2, 
respectively, were used for further downstream analysis. 
2.2.2.2 cDNA synthesis 
Reverse transcription was carried out according to Quantitect Reverse Transcription 
kit protocol (Qiagen). Following elimination of genomic DNA by gDNA wipeout 
buffer (Table 7), a certain amount of RNA was mixed with reverse transcriptase, 
reverse transcription buffer, primer mix, and water in a 20-µl reaction mixture and 
then incubated for 30 min at 42ºC (Table 8). Finally, the reverse transcriptase was 
inactivated by incubation at 95ºC for 3 min. 
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Table 7: The first step of reverse transcription 
Component  Volume  
gDNA Wipeout Buffer, 7× 2 µl 
RNA  Less than 1 µg 
RNase-free water Up to total volume 14 µl 
Table 8: The second step of reverse transcription 
 
 
 
2.2.2.3 Polymerase chain reaction (PCR) and electrophoresis 
PCR was performed using DNA isolated from mouse tissue to genotype the mice. 
Amplification of the DNA by PCR includes three steps: denaturation, cycling, and 
extension (Table 9). Gene specific primer pairs (Table 10) were used to amplify 
DNA. PCR products of the DNA samples were loaded into a 2% agarose gel 
containing 0.03 µg/ml ethidium bromide (Table 3) and the bands were visualized after 
electrophoresis by UV transillumination and photographed using the GenoPlex 
system.  
Table 9: PCR protocol for genotyping 
Component Volume (µl) 
H2O 12.75 
Buffer 5X 5 
Mgcl2 (25 mM) 2 
dNTP (10 nM) 0.5 
Forward Primer (10 µM) 1.25 
Reverse primer  (10 µM) 1.25 
Taq polymerase (units/µl)  0.25 
Template 2 
Final volume  25 
 
 
Component  Volume (µl) 
Quantiscript Reverse Transcriptase 1 
Quantiscript RT Buffer, 5× 4 
Primer Mix (reverse transcription) 1 
RNA (from first step) 14 
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Sequence Annealing Result Application
5'-CTAGGCCACAGAATTGAAAGATCT-3' 55°C, 30 s Genotyping for Cxcr7 loxp mice
5'-GTAGGTGGAAATTCTAGCATCATCC-3' 55°C, 30 s Genotyping for Cxcr7 loxp mice
5'-AGCCTGGCAACTACTCTGACATC-3' 60°C, 45 s Genotyping for Cxcr7/lacZ
5'-CACGGCGTACCATCTTCTTCTTAT-3' 60°C, 45 s Genotyping for Cxcr7/lacZ
5'-AGGGCCGCAAGAAAACTATCC-3' 60°C, 45 s Genotyping for Cxcr7/lacZ
5'-ACTTCGGCACCTTACGCTTCTTCT-3' 60°C, 45 s Genotyping for Cxcr7/lacZ
5'-CTAGGCCACAGAATTGAAAGATCT-3' 55°C, 30 s Genotyping for Cre mice
5'-GTAGGTGGAAATTCTAGCATCATCC-3' 55°C, 30 s Genotyping for Cre mice
5'-GCGGTCTGGCAGTAAAAACTATC-3' 55°C, 30 s Genotyping for Cre mice
5'-GTGAAACAGCATTGCTGTCACTT-3' 55°C, 30 s Genotyping for Cre mice
5'-GCAAGTTTGGGGTACAGTCC-3' 55°C, 30 s Genotyping for Cxcr7 deletion
5'-ACAACAGCCTTACACCTCCC-3' 55°C, 30 s Genotyping for Cxcr7 deletion
5'-CCATCTTACACTACATCCCG-3' 55°C, 30 s Genotyping for Cxcr7 deletion
lox/WT: 396 bp and 362 bp; lox/lox: 
396 bp only; WT/WT: 362 bp only
WT: CXCR7 458 bp, lacZ no band    
Het: Cxcr7 458 bp, lacZ 404 bp          
KO: Cxcr7  no band, LacZ 404 bp
This will not  distinguish Cre 
homozygous from heterozygous 
mice. Internal control = ~324 bp 
Cre fragment = ~100 bp 
2209 bp, without recombination                          
521 bp, with recombination
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2.2.2.4 Quantitative real-time PCR 
Qantitative real-time PCR (qRT-PCR) is a reliable and sensitive technique to quantify 
mRNA expression following reverse transcription into cDNA by determination of the 
crossing points of the amplification curve obtained from incorporated fluorescent 
probes, such as SYBR green. All qRT-PCR runs were carried out by Opticon Real-
Time PCR System or 7900HT Fast Real-Time PCR System according to a general 
protocol (Table 11) using a specific cycler program (Table 12).  
Primer pairs for Cxcr7, Cxcr4, Vldlr, and Ldlr (Table 2) were used for PCR 
amplification in a real-time cycler. Gapdh, β-actin, and rpl13a (Table 2) were used as 
reference genes. The relative values were calculated by QbasePLUS software 
(Biogazelle) and were further log2 transformed for data analysis (145).  
Table 11: Protocol of the qRT-PCR runs 
Component Volume (µl) 
2× Quantitect SYBR Green PCR Master Mix  12.5 
10× QuantiTect Primer Assay 2.5 
Template cDNA (diluted) 2 
RNase-free water  up to 25 
Table 12: Program of the qRT-PCR runs 
Step Tm Time 
Initial activation step 95°C 15 min 
Cycling steps (40 cycles) 94°C 15 s 
 60°C 30 s 
                                                  72°C 30 s 
Plate reading    
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2.2.3 Histological staining protocols 
2.2.3.1 Movat’s pentachrome staining  
After deparaffinization, slides were stained successively with alcian blue, Orcein-
Verhoeff's Hematoxylin, Brilliant Crocein Scarlet MOO, and alcoholic saffron (Table 
13). The pentachrome staining allows differential analysis of nuclei/elastic fibers 
(black), collagen/reticular fibers (yellow), ground substance/mucin (blue), and 
fibrinoid/fibrin intense (red) (146).  
Table 13: Procedure of Movat’ pentachrome staining 
Staining procedure Time Tm 
Xylene 30 min RT 
100% isopropanol 5 min x 2 RT 
96% isopropanol 5 min RT 
70% isopropanol 5 min RT 
Millipore water  5 min RT 
PBS 5 min RT 
Alcian blue solution  (1%)  20 min  RT 
Tap water  5 min RT 
Alkaline alcohol  10 min 56ºC 
Running water  2 min RT 
Millipore water (dip several times) — RT 
Orcein-Verhoeff's Hematoxylin 30 min 37ºC 
Running water 3 min RT 
Iron (III)-Chloride solution (2%)  2 min RT 
Acidic alcohol 2 min RT 
Brilliant Crocein Scarlet MOO solution 10 min RT 
Acetic acid (0.5%) 30 s RT 
Phosphor-tungstic acid (5%)  4 min RT 
Acetic acid (0.5%) 30 s RT 
100% ethanol 1 min x 3 RT 
Alcoholic saffron  (6%, sealed container) 8 to15 min  RT 
Absolute ethanol  3 min x 2 RT 
Xylene (dip several times) — RT 
Vitrocloud solution — RT 
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2.2.3.2 Elastic van Gieson staining 
Elastic van Gieson (EVG) staining was performed according the manual of Elastic 
van Gieson kit (Table 14) using Weigert’s hematoxylin, picrofuchsin, and the 
resorcinol-fuchsin solution. Elastic fibers (black), nuclei (black-brown), collagen 
(red), and muscle (yellow) can be differentially analyzed by the EVG staining (147). 
Table 14: Protocol of EVG staining 
Staining procedure Time Tm 
Xylene 30 min RT 
100% isopropanol 5 min x 2 RT 
96% isopropanol 5 min RT 
70% isopropanol  5 min RT 
Millipore water 5 min RT 
PBS  5 min RT 
Resorcinol-Fuchsine-solution (Roth, X877.1) 15 min 56ºC 
Tap water (dip twice) — RT 
80% ethanol (dip once) — RT 
Tap water (dip once) — RT 
Millipore water  — RT 
Solution A + B (refer to table 3) 5 min RT 
0.5% HCL-alcohol (dip once) — RT 
Tap water (dip once) 5 min RT 
Picrofuchsin 1 min RT 
Tap water (dip once) — RT 
70% ethanol (dip once) — RT 
96% ethanol (dip once) — RT 
100% ethanol (dip once) — RT 
Xylene 5 min RT 
Vitrocloud solution — RT 
2.2.3.3 Oil red O staining 
Lipid deposition in the aorta can be quantified by oil red O staining (148). After an 
overnight incubation in 4% PFA, the adventitia and adipose tissues of the 
thoracoabdominal aorta were gently and completely removed. The aorta was 
dissected, cut longitudinally, and finally en face pinned onto a black rubber plate. 
After washing with running tap water, the aorta was rinsed with 60% isopropanol (10 
dips), followed by staining with the oil red O solution (Table 3) for 15 min. The 
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stained aorta was rinsed by 60% isopropanol (10 tips) and running tap water. The en 
face prepared aorta was transferred on a glass slide and coverslipped with glycerin 
mounting solution (Table 3). Digital images of aorta were recorded using a 
microscope (Leica DM 2500) equipped with a CCD camera (JVC) and Diskus 
software (Hilgers, Bonn). The lesional area (oil red O positive) was quantified by 
Image J software (National Institute of Health, USA), and expressed as the percentage 
of the positive area relative to the whole aortic area.  
2.2.3.4 Histomorphometry 
Histomorphometry is a useful technique to measure and characterize the 
microscopical images including quantification and comparison of target geometric 
areas and perimeters. 
Cross-sections (4 µm thickness, 6 sections/mouse) of the left common carotid 
arteries were selected within a standardized distance (80 to 320 µm) from the 
bifurcation and subsequently stained with modified Movat’s pentachrome or EVG 
stain. Cross-sections (4 µm thickness, 4 sections/mouse) of the aortic roots were 
selected within a standardized distance (40 to 160 µm) from the first section in which 
three leaflets were visible and subsequently stained with modified Movat’s 
pentachrome or EVG stain. Lumen area, lumen area inside the internal elastic lamina 
(IEL), lumen area inside the external elastic lamina (EEL), and the aortic root plaques 
were determined using image analysis software (Diskus, Hilgers, Bonn). These data 
were used to calculate neointimal and medial areas as follows: neointimal area =IEL 
area − lumen area; medial area = EEL area − IEL area. 
2.2.3.5 β-galactosidase activity assay 
A β-galactosidase (β-gal) activity assay is commonly used to analyze expression of 
the reporter gene lacZ, which encodes for β-gal from E. coli. In the X-gal assay, the 
activity of β-gal is visualized using the β-gal substrate 5-bromo-4-chloro-indolyl-β-D-
galactopyranoside (X-gal), which is converted to 5,5'-dibromo-4,4'-dichloro-indigo 
(an insoluble blue dye) (149). 
To determine the Cxcr7 promoter activity in different tissues, Cxcr7+/lacZ and 
Cxcr7+/+ mice were perfused with 10 ml of ice-cold 2% PFA. Tissues were harvested 
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and post-fixed in 2% PFA for 15 min on ice. Following a washing step (PBS 
containing 2 mM MgCl2), tissues were incubated in the staining solution (Table 3) 
overnight at 37ºC (149). Subsequently, the stained tissues were frozen and embedded 
in Tissue-Tek® O.C.T. compound for cryosectioning by cryostats (Leica CM3050 S). 
Cryosections (5-10 µm thickness) were re-stained with the staining solution overnight 
at 37ºC and nuclei were counterstained with Nuclear Fast Red. The sections were 
coverslipped with Vitro-Clud mounting medium. 
2.2.4 Immunofluorescence staining protocols 
Immunofluorescence staining is a technique to identify proteins in tissues or cells 
using specific primary antibodies. Staining was carried out on cryosections or paraffin 
embedded sections. All stainings were performed according to specific protocols 
(Table 15). Corresponding secondary antibodies (Abs) conjugated to a fluorescence 
dye were used to visualize the primary Abs. Nuclei were counterstained with 4’, 6-
diamidino-2-phenylindole (DAPI). 
For Cxcr7 immunostaining, cryosections (fixed in 4% PFA) from wild type 
mice were used and compared to sections from Cxcr7lacZ/lacZ mice, which served as 
negative controls (Table 14). After antigen retrieval and a blocking step (10% horse 
serum in PBS containing 0.2% Triton X-100), slides were incubated with a 
monoclonal anti-human CXCR7 Ab (10 µg/ml, 4ºC, and overnight), followed by 
incubation with a donkey-anti-mouse IgG-FITC-conjugated Ab (1:100, RT, and 1 h). 
Murine isotype IgG was used for negative control stainings on sections of the carotid 
artery with neointima. 
Several sections of the carotid arteries or aortic roots (4 per mouse, fixed in 
4% PFA, and paraffin-embeded) were used for α-SMA, SM22, and Mac-2 staining 
(Table 15 and 16). Slides were blocked with PBS containing 10% goat serum (for 
SM22 staining) or 1% BSA and 2.5% horse serum (for α-SMA and Mac-2 staining). 
After the blocking step, slides were incubated with a monoclonal anti-mouse α-SMA 
Ab (1:200, 4ºC, and overnight), a rabbit polyclonal anti-SM22 Ab (1:200, 4ºC, and 
overnight), or a monoclonal anti-mouse Mac-2 Ab (1:400, 4ºC, and overnight). 
Subsequently, the Mac-2 Ab was visualized by a donkey-anti-rat IgG-FITC-
conjugated Ab (1:100, RT, and 30 min) or a donkey-anti-rat IgG-cy3-conjugated Ab 
(1:300, RT, and 30 min). The α-SMA Ab was detected by a donkey-anti-mouse IgG-
FITC-conjugated Ab (1:100, RT, and 30 min), and the SM22 Ab was visualized by a 
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goat-anti-rabbit IgG-Dylight549-conjugated Ab (1:200, RT, and 30 min). Appropriate 
non-specific control Abs in the same concentration as the primary Abs were used as 
negative controls (Table 16).  
Digital images were recorded using a fluorescence microscope (Leica DM 
2500) equipped with a CCD camera (JVC) and Diskus image acquisition software. 
The positively stained area per neointima was quantified with Image J (National 
Institute of Health, USA); the relative SMCs content was evaluated by dividing the α-
SMA- or SM22-positive area by the whole neointimal or plaque area. The 
macrophage number per lesion was determined by counting the DAPI-stained nuclei 
in the Mac-2 positive area. 
Table 15: Immunostaining protocols 
Procedure Method and material 
Deparaffinization Xylene: 2 × 15 min 
100% ethanol: 2 × 5 min 
96% ethanol: 1 × 5 min 
70 % ethanol: 1 × 5 min                                                 
PBS: 1 × 5 min 
Antigen retrieval Cooking in Sodium Citrate Buffer for 15 min 
Blocking PBS containing 10% goat serum or 1% BSA and 
2.5% horse serum 
Primary antibody incubation Appropriate antibody (Table 16) 
Second antibody incubation Appropriate antibody (Table 16) 
Counterstaining  and mounting Vectashield Mounting Medium with DAPI 
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 Table 16: Antibodies for immunostaining 
Antibody  Clone Ig type Conjugate  Manufacturer 
Monoclonal anti-human 
alpha-SMA  Ab 
1A4 Mouse IgG2a, κ Purified  Dako 
Monoclonal anti-mouse 
MAC-2 Ab 
M3/38 Rat Ig2a Purified  Cedarlane 
Monoclonal anti-human 
CXCR7/RDC1 Ab 
11G8 Mouse IgG1 Purified  ChemoCentryx. 
Inc/R&D 
Rabbit polyclonal anti-
SM22 Ab 
— — Purified  Abcam 
Mouse IgG — — Purified  SANTA CRUZ 
Rat IgG — — Purified  SANTA CRUZ 
Donkey anti-mouse IgG 
(H+L) Ab 
— — cy3 Jackson 
ImmunoReserch 
Donkey-anti-mouse IgG 
(H+L) Ab 
— — FITC Jackson 
ImmunoReserch 
Donkey-anti-rat (H+L) 
Ab 
— — cy3 Jackson 
ImmunoReserch 
Goat-anti-rabbit IgG 
(H+L) Ab 
— — Dylight549 KPL 
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2.2.5 Flow cytometry  
Flow cytometry is a biophysical technology for counting, sorting, and biomarker 
analysis of cells or particles. The advantage of flow cytometry is the rapid and 
simultaneous multi-parametric analysis (size, granularity and fluorescent intensity) of 
a cell suspension on a single cell level dependent on light scatter and fluorescence. 
Blood (approximately 100 µl) was obtained from the retro-orbital sinus and 
collected in EDTA-coated tubes before adding erythrocyte lysis buffer (3 ml, at RT 
for 10 min).  
To quantify murine Sca-1+lin-/lo peripheral blood progenitor cells (SPCs) (Fig. 
5), blood cells were incubated with phycoerythrin (PE)-conjugated anti-mouse Sca-1 
(1:50 dilution; Table 17) and the biotinylated anti-mouse hematopoietic lineage Ab 
panel (CD3, CD45R, CD11b, Ter-119, and Ly-6G, 1:50 dilution of each Ab; Table 
17) on ice for 30 min followed by streptavidin phycoerythrin-Cy7 (1:500 dilution, for 
30 min on ice; Table 17). The same gating strategy was applied to identify Sca-1+lin-
/lo
 cells in all experiments (Fig. 5). 
Table 17: Antibodies for flow cytometry 
Antibody  Clone Ig type Conjugate  Manufacturer 
Monoclonal anti-
human/mouse CXCR7 Ab 
8F11-M16 Mouse 
IgG2b 
PE Biolegend 
Monoclonal anti-
human/mouse IgG2b Ab 
MPC11 Mouse 
IgG2b 
PE Biolegend 
Mouse IgG2b — — Biotinylated eBioscience 
Monoclonal anti-mouse 
Ly-6A/E (Sca-1) Ab 
D7 Rat 
IgG2a,κ 
PE eBioscience 
Monoclonal anti-mouse 
CD115 Ab 
AFS98  Rat IgG2a, 
κ 
PE eBioscience 
Monoclonal anti-mouse 
Gr-1 Ab 
RB6-8C5 Rat IgG2a, 
κ 
PerCP-
Cy*5.5 
BD Biosciences 
Mouse hematopoietic 
lineage flow panel 
— — Biotinylated eBioscience 
Streptavidin 
phycoerythrin-cy7 
— — cy7 eBioscience 
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Figure 5. Gating strategy of Sca-1+lin-/lo peripheral blood progenitor cells 
(PBPCs) by flow cytometry. (A) The cell population of interest (R1) excluding 
platelets, cell debris, monocytes, and neutrophils was gated in a forward (FSC) vs. 
side scatter (SSC) dot plot. (B) The cell population in the R1 gate was further 
analyzed for the expression of Sca-1 (stem cell marker) and hematopoietic lineage 
markers (Lineage), including CD3 (T cell marker), Ter-119 (erythroid cells), CD45R 
(lymphocytes), CD11b (monocytes/neutrophils), and Ly-6G (monocytes/neutrophils). 
Sca-1+lin-/lo cells were quantified in the R2 gate.  
To quantify murine monocyte subtypes (Fig. 6), blood cells were treated with 
biotinylated anti-mouse CD3, CD45R, and Ter-119 antibodies (1:50 dilution of each 
Ab) on ice for 30 min, followed by incubation with streptavidin phycoerythrin-Cy7 
(1:500 dilution), PE-conjugated Ab against CD115 (1:100) and an PerCP-Cy*5.5-
conjugated Gr-1 Ab (1:100) on ice for 30 min  
 
Figure 6. Gating strategy of monocyte subtypes by flow cytometry. (A) The 
leukocyte population (R1) was gated in a FSC vs. SSC dot plot. (B) The monocyte 
population (R2) was identified as CD115+ and CD3-/loTer-119-/loCD45R-/lo. (C) 
Monocytes were divided into two subtypes defined as CD115+ Gr-1+ (R4) and 
CD115+ Gr-1-/lo (R3). 
To analyze Cxcr7 protein expression on the cell surface, different cell suspensions 
were stained with an anti-human/mouse CXCR7 Ab (Table 17) conjugated with 
phycoerythrin. Cells from Cxcr7-/- mice or a PE-conjugated anti-human/mouse IgG2b 
Ab were used as negative controls. 
                                                                                                      MATERIALS AND METHODS 
 
35 
 
Data were collected using a flow cytometry (FACSCantoTM II) and analyzed using 
FlowJo software (TreeStar, Inc., Ashland, USA). 
2.2.6 Cxcl12 ELISA  
Cxcl12 plasma concentrations were measured following centrifugation (10000g, 4°C, 
and 15 min). Bone marrow extracellular fluid of femurs was flushed with pre-cold 
PBS (500 µl), and then the supernatant was obtained after centrifugation (300g, 5 
min). Plasma, bone marrow supernatant, and a series of standards were incubated in 
wells of a microplate coated with anti-mouse Cxcl12 (2.5 h, RT, and gentle shaking). 
After thoroughly washing, the plate was incubated with a biotinylated anti-mouse 
Cxcl12 Ab (1 h, RT, and gentle shaking). Following the second washing step, the 
streptavidin solution was added to the wells (45 min, RT, and gentle shaking). After 
the third washing step, TMB one-step substrate reagent was added to the wells (30 
min, RT, and gentle shaking in the dark). The absorbance in each well was read at 450 
nm (Infinite M200) after quenching the reaction using the stop solution. The standard 
curve created by the standard concentration and absorbance was used to determine the 
Cxcl12 concentration in the samples. Additionally, the Cxcl12 concentration in the 
bone marrow was standardized to the protein concentration measured with DC Protein 
Assay Kit. Absorbance was measured at 450 nm using a plate reader (Infinite M200). 
2.2.7 Two-photon laser scanning microscopy  
Two-photon laser scanning microscopy (TPLSM) is a novel three-dimensional 
fluorescence imaging technique based on the excitation of fluorophores by the non-
linear absorption of two photons (150, 151). This technology could investigate viable 
tissues with enhanced penetration depth and imaging resolution, and decreased 
background and phototoxicity (150, 151).  
2.2.7.1 LacZ staining of the carotid artery   
Intact arteries were first incubated with chloroquine reagent (300 µM in HBBS, 
ImaGene Green C12 FDG lacZ Gene Expression Kit) for 30 min at 37ºC to inhibit 
endogenous lysosomal β-D-galactosidase activity. For imaging, arteries were 
mounted in a perfusion chamber that was then filled with HBSS (GIBCO™, 10×, 1: 
10 diluted) and the temperature of artery was constantly maintained at 37ºC by a 
heating platform. To assess the lacZ reporter gene activity, C12 fluorescein di-β-D-
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galactopyranoside (C12 FDG, ImaGene Green, Invitrogen, 33 µM in HBBS) was 
administered intraluminally with a pressure of 60 mmHg for 90 min. Phenylethyl β-
D-thiogalactopyranoside (PETG, ImaGene Green, 1mM in HBBS) was applied to 
stop the β-gal reaction. Dead cells were excluded by propidium iodide staining to 
assure that the lacZ signal was only derived from viable cells. Prior to imaging, 
intraluminal pressure was restored. Arteries were imaged with a multi-photon system 
(TriM Scope, LaVision Biotec GMBH, Bielefeld, Germany) in single beam mode 
coupled to a motorized up-right microscope (Olympus BX61WI with a 20× NA 0.95 
water immersion objective; Olympus GmbH, Hamburg, Germany). For two-photon 
excitation, the pulsed Ti-Sapphire laser (MaiTai HP, Spectra Physics, Mountain View, 
US) was tuned to 830 nm for visualization of SHG (second harmonic generation) 
signals of collagen, C12 FDG, and autofluorescence signals originating from the 
elastic lamina. Emitted fluorescent signals were detected with PMTs (two-photo 
multiplier tubes) tuned to corresponding parts of the emission spectra: SHG, 453-497 
nm (PMT 1); C12 FDG, 500-550 nm (PMT 2); autofluorescence signals of elastin 
were detected in both in PMT 1 and PMT 2. Series of x-y plane images were obtained 
at successive depth (z-stack) using ImSpector Pro 4.0.43 acquisition software 
(LaVision Biotec GMBH). Further image processing was performed using Image-Pro 
3D analyzer 7.0 (Media Cybernetics, Silver Spring, USA) 
2.2.7.2 DiI-VLDL uptake into adipose tissues 
Intact adipose tissue that was still connected to the circulation was mounted in a 
perfusion chamber. The chamber was filled with HBSS and the temperature was 
constantly maintained at 37ºC. Adipose tissues were embedded in agarose gels (3% 
agarose in HBSS), covered with a coverslip (0.17 mm thick), and imaged using the 
Fluoview FV1000-MPE multi-photon system (Olympus Deutschland GmbH, 
Hamburg, Germany) coupled to a MaiTai® DeepSee™ HP-DS laser (Newport 
Spectra-Physics GmbH, Darmstadt, Germany). To determine the autofluorescence of 
the adipose tissues, images were taken at 730 nm before dye injection. The mice were 
perfused with PBS to remove DiI-VLDL from the vascular lumen 1 h after IV 
injection of 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate-
labeled VLDL (50 µg/ 20 g, DiI-VLDL; Kalen Biomedical, Montgomery Village, 
USA). To detect the emitted fluorescent signals, two ultra-sensitive external non-
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descanned PMT detectors were tuned to the emission spectra of tissue 
autofluorescence (495–540 nm) and the DiI dye (575–630 nm). Images (1024 × 1024 
pixels) were obtained in the x–y plane using image acquisition software (FV10-ASW 
Ver3.0; Olympus). 
2.2.8 Quantification of cholesterol and DiI concentration in murine tissues 
The VAT (approximately 30 µg) was homogenized in 1 ml cell lysis buffer by using 
TissueLyser LT homogenizer. The cholesterol concentration was determined using a 
cholesterol assay kit (as described in chapter 2.1.2) and normalized to the protein 
concentration in the samples, which was measured with DC Protein Assay Kit. 
Absorbance was measured at 450 nm using a plate reader (Infinite M200). 
The VAT and liver were harvested from mice injected with DiI-VLDL after 
perfusion with PBS. The harvested tissues were homogenized in cell lysis buffer 
(Table 2) using a TissueLyser LT homogenizer and tissue lysates were obtained after 
centrifugation (14000 g, 4°C, and 10 min). The DiI fluorescence intensity was 
measured in the tissue lysates (excitation wavelength: 514 nm; emission wavelength: 
565 nm) using a microplate reader (Infinite M200). A standard curve was created 
using a series of known concentrations of DiI-VLDL. DiI concentration in the lysates 
was normalized to the protein concentration in the corresponding samples. 
2.2.9 SVEC culture protocol 
SVEC is a murine lymphoid EC line transfected with virus-40 (152). SVECs were 
grown to approximately 70% confluence in 6-well plastic tissue culture plates. Then, 
these cells were treated with medium alone or medium containing TNF-α (10 ng/ml) 
and IL-1β (10 ng/ml) for 5 h. Finally, cells were harvested for flow cytometry 
analysis (110).  
2.2.10 Statistical analysis 
Data represent the mean ± SEM. The Student's t-test or 1-way ANOVA followed by 
Newman-Keuls posttest were used for statistical comparison between groups (Prism, 
GraphPad Software, La Jolla, USA). P values ≤ 0.05 were considered statistically 
significant. 
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3. RESULTS 
3.1 Cxcr7 expression patterns 
Firstly, the Cxcr4 and Cxcr7 mRNA expression levels were compared between 
leukocytes and different murine tissues by qRT-PCR. Cxcr7 mRNA was ubiquitously and 
abundantly expressed in most of the tissues studied, such as arteries, heart, kidney, lung, 
spleen, and adipose tissue (Fig. 7); however, compared to these tissues, the Cxcr7 mRNA 
expression was significantly lower in the bone marrow, liver, and leukocytes. Conversely, 
Cxcr4 mRNA expression was lower in the arteries, heart, and kidney compared to bone 
marrow and leukocytes. In addition, increased expression of Cxcr4 was found in the lung, 
spleen, and adipose tissue (Fig. 7). Following vascular injury of the carotid artery in 
Apoe-/- mice, the mRNA expression of Cxcr4 was significantly increased after 1 and 2 
wks, while the Cxcr7 expression was unaltered compared to uninjured carotid arteries 
(Fig. 8). In summary, the transcriptional expression pattern of Cxcr7 differs substantially 
from that of Cxcr4 except in the lung, spleen, and adipose tissue, where both Cxcr7 and 
Cxcr4 are highly expressed.  
 
Figure 7. Cxcr7 and Cxcr4 mRNA expression pattern in Apoe-/- mice. Transcripts for 
Cxcr7 and Cxcr4 were quantified in leukocytes and various tissues of mice by qRT-PCR 
(n = 3 mice per group). *P < 0.0001 versus carotid artery.  
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Figure 8. Cxcr7 and Cxcr4 mRNA expression after carotid injury in Apoe-/- mice. 
Quantification of Cxcr7 and Cxcr4 mRNA levels in normal (control, n = 11) and injured 
carotid arteries (n = 5 to 6 mice per group). ***P < 0.0001, versus normal carotid arteries 
at the indicated time points after vascular injury.  
To study the cellular localization of the Cxcr7 expression, Cxcr7 promoter activity 
was studied in different tissues of Cxcr7lacZ/+ mice by X-gal staining. Activity of the 
reporter protein, β-gal, indicating Cxcr7 transcription, was detectable in the marginal 
and/or sinusoidal zones of the spleen, in epithelial cells of kidney, lung, spleen, and in 
cardiomyocytes, but not in hepatocytes (Fig. 9). In the kidney, intensive X-gal staining 
was also detectable in the glomeruli. Moreover, X-gal staining was observed in the 
endothelial and adventitial cells of the aorta, and in the endothelium covering the aortic 
valves.  
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Figure 9. X-gal staining in tissues from Cxcr7+/lacz and Cxcr7+/+ mice. Representative 
images of X-gal staining are shown (n = 3 mice per mice). Scale bars, 200 µm.  
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The cellular localization of Cxcr7 expression in the carotid arteries was further 
studied by TPLSM in ex vivo perfused carotid arteries of Cxcr7+/lacZ and Cxcr7+/+ mice 
using a β-gal substrate that is converted to a fluorescent dye by β-gal. Cxcr7 reporter 
expression was detectable in the ECs but not in the SMCs of carotid arteries by TPLSM 
(Fig. 10). Thus, Cxcr7 transcription was primarily found in the endothelium of arterial 
vessels. 
  
Figure 10. β-gal activity in the endothelium of carotid arteries from Cxcr7+/lacz and 
Cxcr7+/+ mice. Representative images of lacZ+ cells (green) obtained by TPLSM in the 
viable carotid arteries (n = 3 mice per group). Arrows indicate positive staining. 
Arrowheads indicate internal and external elastic membranes. Stars represent collagen 
(blue autofluorescence). 
Next, Cxcr7 protein expression was investigated in different murine tissues by 
immunostaining. Cxcr7 protein expression was not detectable in the liver and carotid 
arteries by immunostaining. In accordance with the Cxcr7 promoter activity, Cxcr7 
positive immunostaining was found in the spleen, kidney, and endothelium of the aortic 
valves (Fig. 11). Co-staining for Cxcr7 and CD31 further confirmed that Cxcr7 
expression was restricted to the CD31+ ECs in the leaflets of the aortic valve (Fig. 12). 
However, Cxcr7 immunostaining was absent in neointimal macrophages, SMCs, and ECs 
of the carotid artery (Fig. 11 and 13).  
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Figure 11. Cxcr7 protein expression patterns. (A) Immunostaining of Cxcr7 in the 
spleen, kidney, the aortic root, liver, and carotid artery from Cxcr7+/+ was performed. 
Cxcr7-/- mice served as negative controls (n = 3 mice per group). Scale bars, 200 µm. The 
rectangle shows a high magnification view of the positive area indicated by the arrows.  
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Figure 12. Endothelial expression of Cxcr7. Double-immunostaining of Cxcr7 and 
CD31 in aortic valves (n = 3 mice per group). Arrows point to the co-stained area. Scale 
bars, 200 µm. 
 
Figure 13. Absence of Cxcr7 protein expression in the neointima of carotid artery. 
(A) Immunostaining of Cxcr7 (11G8 antibody) was performed in the neointima of carotid 
arteries from Apoe-/- mice. Negative control stainings were performed using isotype IgG 
(n = 3 mice per group). Scale bars, 50 µm.  
In addition, Cxcr7 protein expression was analyzed on hematopoietic cells by flow 
cytometry (Fig. 14). Cxcr7 was not detectable in murine peripheral leukocytes, bone 
marrow cells, or platelets. Expression of Cxcr7 was found on unstimulated SVECs, and 
on SVECs activated with TNF-α and IL-1β.  
In summary, Cxcr7 promoter activity and expression at the mRNA and protein 
level were consistently present in the spleen and in ECs of aortic valves. 
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Figure 14. Cxcr7 protein expression on murine hematopoietic cells and ECs. Cxcr7 
expression on leukocytes, bone marrow cells, or platelets from Cxcr7+/+ (open histogram) 
and Cxcr7-/- mice (shaded histogram) was studied by flow cytometry (n = 3 per group). 
SVECs (isotope control antibody, shaded histogram; Cxcr7 antibody, dotted histogram) 
and activated SVEC (treated with 10 ng/ml TNF-α and 10 ng/ml IL-1β for 5 h, open 
histogram with solid line) served as positive control. Representative data from three 
independent experiments are shown. 
3.2 Role of Cxcr7 on neointima formation 
3.2.1 Conditional Cxcr7 deletion exacerbated neointimal hyperplasia 
To explore the function of Cxcr7, an inducible Cxcr7 knockout model was established by 
using CAG-Cre+Cxcr7floxApoe-/- mice in which Cxcr7 is deleted following activation of a 
ubiquitously expressed Cre-recombinase by TMX. CAG-Cre-Cxcr7floxApoe-/- mice served 
as controls. Firstly, Cxcr7 deletion was confirmed by Cxcr7 immunostaining and semi-
quantitative PCR with Cxcr7-specific primers. In contrast to CAG-Cre-Cxcr7floxApoe-/- 
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mice, Cxcr7 immunostaining was no longer observed in the spleen at 2 wks after TMX 
treatment (Fig. 15). Moreover, the band intensity of the Cxcr7 product amplified from 
genomic DNA of CAG-Cre+Cxcr7floxApoe-/- mice was substantially reduced compared to 
CAG-Cre-Cxcr7floxApoe-/- mice at 2 wks after TMX treatment (Fig. 16). Therefore, 
knockdown of Cxcr7 in CAG-Cre+Cxcr7floxApoe-/- mice was verified at the protein level 
in the spleen and deletion of the Cxcr7 gene was detected at the DNA level. 
 
Figure 15. Cxcr7 was efficiently deleted by Cre-recombinase in the spleen. Cxcr7 
immunostaining (green) was performed in spleen sections from CAG-Cre-Cxcr7floxApoe-/- 
and CAG-Cre+Cxcr7floxApoe-/- mice at 2 wks after TMX treatment (n = 4 mice per group). 
Representative images are shown. Arrows indicate the Cxcr7 positive staining. Scale bars, 
200 µm. 
 
Figure 16. The Cxcr7 gene was deleted by Cre-recombinase activation. Semi-
quantitative PCR with specific primers for Cxcr7, Cre-recombinase, and an internal 
control was performed on genomic DNA samples, which were isolated from the tails of 
CAG-Cre-Cxcr7floxApoe-/- and CAG-Cre+Cxcr7floxApoe-/- mice 2 wks after TMX treatment 
(n = 2 mice per group). A representative gel is shown.  
To evaluate the function of Cxcr7 in the neointima formation, vascular injury was 
carried out in CAG-Cre+Cxcr7floxApoe-/- mice and CAG-Cre-Cxcr7floxApoe-/- mice 2 wks 
after TMX treatment. The neointimal area was increased in the carotid arteries of TMX-
treated CAG-Cre+Cxcr7floxApoe-/- mice fed a HCD at 4 wks after vascular injury 
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compared to TMX-treated CAG-Cre-Cxcr7floxApoe-/- mice (Fig. 17). However, the medial 
area was not significantly different between these two groups (Fig. 17).  
 
Figure 17. Effect of Cxcr7 deficiency on neointima formation. The neointimal and 
medial areas were quantified by planimetry in EVG-stained sections of carotid arteries 4 
wks after wire injury in Apoe-/- mice in which Cxcr7 was deleted by an ubiquitously 
expressed Cre-recombinase after TMX treatment (CAG-Cre+Cxcr7floxApoe-/- mice). TMX-
treated CAG-Cre-Cxcr7floxApoe-/- mice that do not express Cre-recombinase were used as 
controls (n = 8 mice per group). Representative images of the EVG-stained carotid 
sections are shown. Scale bars, 100 µm; *P< 0.05. 
The effects of Cxcr7 deficiency on the cellular composition of the neointima were 
determined by immunostaining of macrophage-specific Mac-2 or SMC-specific α-SMA. 
The number of Mac-2 immunopositive cells in the neointima was significantly higher in 
CAG-Cre+Cxcr7floxApoe-/- than in CAG-Cre-Cxcr7floxApoe-/- mice (Fig. 18A). In contrast, 
the α-SMA immunopositive area in the neointima was not significantly different between 
Cre+Cxcr7floxApoe-/- and CAG-Cre-Cxcr7floxApoe-/- mice (Fig. 18B). These results indicate 
that Cxcr7 deficiency increases the accumulation of macrophages in the neointimal 
lesions, whereas Cxcr7 does not affect the relative neointimal SMC content. 
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Figure 18. Effects of Cxcr7 deficiency on the cellular composition of the neointima. 
Quantification of the neointimal macrophage cell number (A) and the relative SMC 
content (B) was performed by Mac-2 and α-SMA immunostaining, respectively. 
Representative images of Mac-2 and α-SMA immunostainings are shown (n = 6 to 8, *P 
< 0.05). Scale bars, 100 µm. 
The Cxcl12/Cxcr4 axis plays a crucial role in neointima formation via 
mobilization of SPCs after vascular injury (88, 89, 153). To test whether Cxcr7 affects the 
Cxcl12-mediated SPC mobilization following vascular injury, circulating levels of Sca-
1+Lin- cells were measured 1 d before and 1 d after vascular injury. The injury-induced 
increase of Sca-1+Lin- cells at 1 d after injury was similar in CAG-Cre+Cxcr7floxApoe-/- 
and CAG-Cre-Cxcr7floxApoe-/- mice (Fig. 19), suggesting that Cxcr7 is not involved in the 
mobilization of SPCs after vascular injury.  
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Figure 19. Effects of Cxcr7 deficiency on injury-induced SPC mobilization. The Sca-
1+/Lin- cell population was measured at 1 d before (baseline) and 1 d after carotid injury 
in CAG-Cre+Cxcr7floxApoe-/- and CAG-Cre-Cxcr7floxApoe-/- mice (n = 7 to 8, *P < 0.05, 
the values after injury versus the corresponding baseline. 
Cxcr7 can internalize and degrade Cxcl12, thus modulating the extracellular 
availability of Cxcl12 (132, 134). To study whether Cxcr7 affects the levels of Cxcl12 in 
the plasma and bone marrow after vascular injury, Cxcl12 concentrations were 
determined by ELISA. The Cxcl12 levels in the plasma and in the bone marrow of CAG-
Cre+Cxcr7floxApoe-/- mice were higher than in CAG-Cre-Cxcr7floxApoe-/- mice at 4 wks 
after injury (Fig. 20), suggesting that Cxcr7 might regulate the Cxcl12 concentration in 
the plasma and bone marrow in a similar way.  
 
Figure 20. Effects of Cxcr7 deficiency on Cxcl12 concentrations. Cxcl12 levels were 
quantified in the plasma (A, n = 9, **P < 0.01) and bone marrow (B, n = 5, **P < 0.01) 
of CAG-Cre+Cxcr7floxApoe-/- and CAG-Cre-Cxcr7floxApoe-/- mice 4 wks after carotid 
injury by ELISA. 
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The role of hypercholesterolemia in the protective effects of Cxcr7 on neointima 
formation was investigated in CAG-Cre+Cxcr7floxApoe+/+ and CAG-Cre-Cxcr7floxApoe+/+ 
mice, which develop only a mild hyperlipidemia in response to a HCD. Interestingly, the 
neointima formation was not significantly different between CAG-Cre+Cxcr7floxApoe+/+ 
and CAG-Cre-Cxcr7floxApoe+/+ mice (Fig. 21). The medial area was also similar between 
these groups (Fig. 21). Thus, these data indicate that hypercholesterolemia in Apoe-/- mice 
crucially determines the effect of Cxcr7 on the neointima formation. 
 
 
Figure 21. Cxcr7 deficiency in Apoe+/+ mice did not affect neointima formation. 
Quantification of the neointimal and medial areas in carotid arteries 4 wks after wire 
injury in Apoe+/+ mice fed a HCD in which Cxcr7 was deleted by activation of 
ubiquitously expressed Cre-recombinase via TMX (CAG-Cre+Cxcr7floxApoe+/+ mice). 
TMX-treated CAG-Cre+Cxcr7floxApoe+/+ mice that do not express Cre-recombinase 
served as control. Representative images of EVG-stained carotid sections are shown (n = 
7 to 8 mice per group). Scale bars, 100 µm.  
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To identify the cause for the aggravated neointimal hyperplasia in severe 
hyperlipidemic Cxcr7-/- mice, lipid levels and peripheral monocyte counts were analyzed 
following vascular injury. The serum cholesterol and triglyceride levels were significantly 
increased in Apoe-/- mice compared with Apoe+/+ mice fed a HCD (Figs. 22A and B). 
Notably, the serum cholesterol and triglyceride levels were higher in CAG-
Cre+Cxcr7floxApoe-/- than in CAG-Cre-Cxcr7floxApoe-/- mice after 4 wks of a HCD (Figs. 
22A and B), whereas no significant difference in the serum cholesterol and triglyceride 
levels were observed between CAG-Cre+Cxcr7floxApoe+/+ mice and CAG-Cre-
Cxcr7floxApoe+/+ mice. In parallel to the changes of the lipid levels, peripheral monocyte 
counts were also higher in Apoe-/- than in Apoe+/+ mice (Fig. 22C). Moreover, absence of 
Cxcr7 increased the peripheral monocyte count in Apoe-/- but not in Apoe+/+ mice (Fig. 
22C). Despite the differences in the serum lipid levels, body weights were not altered in 
CAG-Cre+Cxcr7floxApoe-/- compared with CAG-Cre-Cxcr7floxApoe-/- mice after 4 wks of a 
HCD (Fig. 22D). These findings indicate that Cxcr7 limits severe hyperlipidemia and 
monocytosis in Apoe-/- mice. 
 
Figure 22. Effect of Cxcr7 deficiency on hyperlipidemia and hyperlipidemia-induced 
monocytosis. The serum cholesterol levels (A), triglyceride levels (B), and peripheral 
monocyte counts (C) were measured in TMX-treated CAG-Cre-Cxcr7flox and CAG-
Cre+Cxcr7flox mice (either Apoe+/+ or Apoe-/- mice) fed a HCD 4 wks after injury (n = 4 to 
10 mice per group). *P < 0.05. (D) The body weight of CAG-Cre-Cxcr7floxApoe-/- and 
CAG-Cre+Cxcr7floxApoe-/- mice was determined before (0 d) and 4 wks after injury (n = 8 
mice per group). 
 
3.2.2 Role of Cxcr7 in bone marrow cells on neointima formation  
To evaluate the role of Cxcr7 expressed in bone marrow cells on neointima formation, 
vascular injury was carried out in Apoe-/- mice, which were repopulated with bone 
marrow cells from CAG-Cre+Cxcr7floxApoe-/- or CAG-Cre-Cxcr7floxApoe-/- mice and 
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subsequently treated with TMX. Deletion of the Cxcr7 gene in bone marrow cells did 
neither affect neointima formation (Fig. 23), macrophage accumulation (Fig. 24), the 
relative SMCs content (Fig. 24), serum cholesterol levels, triglycerides levels, nor the 
peripheral blood cell counts (Fig. 25) significantly. 
 
 
Figure 23. Cxcr7 deficient bone marrow did not affect neointima formation. 
Quantification of the neointimal and medial areas in carotid arteries 4 wks after wire 
injury in Apoe-/- mice, which were treated with TMX after repopulation with bone 
marrow from CAG-Cre-CXCR7floxApoe-/- or CAG-Cre+CXCR7floxApoe-/- mice. 
Representative images of EVG-stained carotid sections are shown (n = 4 mice per group). 
Scale bars, 100 µm.  
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Figure 24. Cxcr7 deficient bone marrow did not affect the cellular composition of the 
neointima. Quantification of the neointimal Mac-2 immunopositive cell number (A) and 
the relative SMC content (B) was performed in Mac-2 and α-SMA immunostained 
carotid section 4 wks after wire injury in Apoe-/- mice harboring bone marrow from CAG-
Cre-CXCR7floxApoe-/- or CAG-Cre+CXCR7floxApoe-/- mice. Mice were treated with TMX 
after BMT. Arrows delineate the neointima. Representative images of Mac-2 
immunostaining are shown (n = 4 mice per group). Scale bars, 100 µm. 
 
Figure 25. Cxcr7 deficient bone marrow did not affect lipid levels and monocytosis. 
The serum cholesterol levels (A), triglyceride levels (B), and peripheral monocyte counts 
(C) were measured in Apoe-/- mice, which were repopulated with bone marrow from 
CAG-Cre-CXCR7floxApoe-/- or CAG-Cre+CXCR7floxApoe-/- mice 4 wks after injury and 
feeding a HCD. Mice were treated with TMX after the BMT (n = 3 to 4 mice per group). 
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3.3 Pharmacological targeting of Cxcr7 in neointima formation 
3.3.1 Effect of CCX771 treatment on neointima formation 
The effect of the synthetic Cxcr7 ligand CCX771 on neointima formation was studied in 
hyperlipidemic Apoe-/- mice following vascular injury. Subcutaneous injection of 
CCX771 (10 mg/kg) to Apoe-/- mice resulted in mean CCX771 plasma levels of 336 ± 13 
ng/ml after 1 h and 106 ± 5 ng/ml after 12 h as assessed by LC-MS (Fig. 26). 
 
Figure 26. Plasma concentrations of CCX771. CCX771 (10 mg/kg) dissolved in 
vehicle (10% Captisol) was subcutaneously injected to Apoe-/- and the plasma 
concentrations were determined at 1 h and 12 h after injection by LC-MS (n = 9 mice per 
group; ***P < 0.0001 versus 1 h). 
To study the effect of CCX771 on neointima formation, Apoe-/- mice fed a HCD 
were treated daily with CCX771 (10 mg/kg, s.c.) or vehicle (10% Captisol) after wire-
induced carotid injury. In contrast to the effect of Cxcr7 deficiency, CCX771 treatment 
reduced the neointimal area by 39% compared with vehicle treatment at 4 wks after 
vascular injury. However, the medial area of the carotid arteries was not different 
between the CCX771- and vehicle-treated mice (Fig. 27). 
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Figure 27. Effects of CCX771 treatment on neointima formation after vascular 
injury in Apoe-/- mice. The neointimal and medial areas were quantified by planimetry in 
Movat-stained sections of carotid arteries 4 wks after vascular injury in Apoe-/- mice (n= 7 
to 8 mice per group). Representative images of Movat-stained carotid sections are shown. 
Scale bars, 100 µm; *P < 0.05 versus vehicle. 
The effects of CCX771 treatment on the cellular composition of the neointima 
were studied by immunostaining of macrophage-specific Mac-2 antibody or SMC-
specific α-SMA antibody. Treatment with CCX771 reduced the number of Mac-2 
immunopositive cells in neointima (Fig. 28A); however, the relative neointimal α-SMA 
immunopositive area was not significantly different between CCX771- and vehicle-
treated mice (Fig. 28B). These results indicate that CCX771 treatment decreases the 
accumulation of macrophages in the neointima, whereas the relative SMC content in the 
neointima is not altered by CCX771-treament. 
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Figure 28. Effects of CCX771 treatment on the cellular composition of the 
neointima. Quantification of the neointimal Mac-2-immunopositive cell number (A) and 
the neointimal α-SMA-immunopositive area (B) 4 wks after wire injury in carotid 
sections of Apoe-/- mice treated with vehicle or CCX771 (n= 7 to 8 mice per group). 
Arrows delineate the neointima. Representative images of Mac-2 and α-SMA 
immunostainings are shown (n= 7 to 8 mice per group). Scale bars, 100 µm; *P < 0.05. 
To test whether CCX771 treatment affects the Cxcl12-mediated mobilization of 
SPCs, circulating Sca-1+/Lin- cells were quantified 1 d before and 1 d after vascular 
injury by flow cytometry. Similar to the results obtained in mice with a conditional Cxcr7 
knockout, treatment with CCX771 did not affect the injury-induced increase of Sca-
1+/Lin- cells (Fig. 29), suggesting that CCX771 treatment does not interfere with the SPC 
mobilization after vascular injury. 
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Figure 29. Effects of CCX771 treatment on the injury-induced mobilization of Sca-
1+/Lin- cells. The circulating Sca-1+/Lin- cell population at 1 d before (baseline) and at 1 d 
after vascular injury in Apoe-/- mice treated with vehicle or CCX771 (n = 8 to 9 mice per 
group). Representative flow cytometric dot plots are shown. **P < 0.01, *P < 0.05 versus 
the corresponding baseline. 
To explore whether CCX771 treatment alters Cxcl12 levels in the circulation and 
bone marrow, the Cxcl12 concentration was quantified by ELISA at 4 wks after vascular 
injury in Apoe-/- mice that were daily treated with vehicle or CCX771. The Cxcl12 levels 
in the plasma and in the bone marrow were simultaneously increased in CCX771-treated 
compared with vehicle-treated Apoe-/- mice (Fig. 30). Similar to the results obtained in 
CAG-Cre+Cxcr7floxApoe-/- mice, treatment with CCX771 increased the Cxcl12 
concentrations. 
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Figure 30. Effect of CCX771 treatment on the Cxcl12 concentrations. (A) The plasma 
Cxcl12 levels were quantified at 4 wks after vascular injury in Apoe-/- mice treated with 
vehicle or CCX771 (n = 6 to 7 mice per group). *P < 0.05. (B) The Cxcl12 levels were 
quantified at 4 wks after vascular injury in the bone marrow of Apoe-/- mice injected with 
vehicle or CCX771 (n = 3 mice per group). *P < 0.05. 
To identify the cause for the reduced neointimal hyperplasia after CCX771 
treatment in severe hyperlipidemic Apoe-/- mice, the lipid levels and peripheral monocyte 
counts were analyzed at 4 wks after vascular injury in Apoe-/- mice treated daily with 
vehicle or CCX771. The blood cholesterol and triglyceride levels, and the peripheral 
monocyte counts were substantially reduced in CCX771-treated mice compared with 
vehicle-treated mice after 4 wks of a HCD (Fig. 31). To further test whether CCX771 
injection differentially affects the monocyte subpopulations, the number of Gr-1high and 
Gr-1low monocytes were assessed by flow cytometry. Following vascular injury, the 
number of Gr-1high monocytes was increased, whereas the number of Gr-1low monocytes 
was decreased in the hyperlipidemic Apoe-/- mice after 4 wks of a HCD compared to 
baseline (before injury) (Fig. 31). No significant difference of the Gr-1high or Gr-1low 
monocyte cell counts was observed between CCX771- and vehicle-treated mice 4 wks 
after vascular injury (Fig. 31). These data suggest that CCX771 treatment ameliorates 
severe hyperlipidemia and monocytosis in Apoe-/- mice irrespective of the monocyte 
subpopulations.  
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Figure 31. Effects of CCX771 treatment on hyperlipidemia and hyperlipidemia-
induced monocytosis. The serum cholesterol levels (A), triglyceride levels (B), and 
peripheral monocyte counts (C) were quantified 4 wks after vascular injury and treatment 
with CCX771 or vehicle in Apoe-/- mice fed a HCD (n = 5 to 7 mice per group). *P < 
0.05. (D) The percentage of Gr-1high or Gr-1low monocytes before and 4 wks after vascular 
injury was studied by flow cytometry (n = 4 mice per group). *P < 0.05. 
To determine potential side effects of CCX771 on liver and kidney, serum AST 
and creatinine levels were assessed. The AST and creatinine levels in Apoe-/- mice at 4 
wks after vascular injury (Fig. 32A and B) were not significantly altered after CCX771 
compared with vehicle treatment, suggesting that short-term treatment with CCX771 is 
not associated with hepatotoxicity and does not impair renal function. Moreover, the body 
weights and weight gain of mice treated with CCX771 for 4 wks were not significantly 
different from vehicle-treated mice (Fig. 32C), indicating that CCX771 treatment for 4 
wks is not associated with a severe toxicity that affects food intake and weight gain.  
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Figure 32. Assessment of toxicities of the CCX771 treatment. The serum AST (A) and 
serum creatinine levels (B) were quantified in Apoe-/- mice on a HCD after treatment with 
CCX771 or vehicle for 4 wks (n = 6 to 7 mice per group). (C) The body weights of Apoe-
/-
 mice treated with CCX771 or vehicle was measured before (0 d) and 4 wks after 
vascular injury (n = 4 mice per group).  
3.3.2 Role of splenic Cxcr7 expression in the effects of CCX771 treatment on 
neointima formation 
The spleen is involved in lipid metabolism under hyperlipidemic conditions and is a 
major reservoir of monocytes (154-156). Because Cxcr7 is highly expressed in the spleen, 
the hypothesis that the splenic Cxcr7 expression is required for the effects of CCX771 on 
neointima formation and hyperlipidemia was studied in splenectomized Apoe-/- mice. 
Treatment with CCX771 reduced the neointimal area of Apoe-/- mice at 4 wks after 
vascular injury also in the absence of the spleen (Fig. 33), suggesting that the splenic 
Cxcr7 expression is dispensable for the role of CCX771treatment on neointima formation.  
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Figure 33. Effects of CCX771 treatment on neointima formation in splenectomized 
Apoe-/- mice. Splenectomized Apoe-/- mice fed a HCD were treated with vehicle or 
CCX771 for 4 wks after vascular injury. The neointimal area was measured in EVG-
stained sections of the carotid artery by planimetry (n = 4 mice per group). Representative 
images of EVG-stained carotid sections are shown. *P < 0.05; Scale bars, 200 µm. 
To analyze whether the effects of CCX771 treatment on the lipid levels and 
monocyte count are mediated by the splenic Cxcr7 expression, cholesterol levels and 
circulating monocytes were measured in the splenectomized Apoe-/- mice treated with 
CCX771 or vehicle at 4 wks after vascular injury. The serum cholesterol levels and 
peripheral monocyte counts were reduced in the splenectomized Apoe-/- mice injected 
with CCX771 compared with vehicle-treated mice (Fig. 34). These results indicate that 
the effect of CCX771 on hyperlipidemia and hyperlipidemia-induced monocytosis is not 
mediated by splenic Cxcr7 expression, because CCX771 treatment reduced serum 
cholesterol and peripheral monocytes also in mice without spleens.  
  
Figure 34. Effects of CCX771 treatment on serum cholesterol levels and peripheral 
monocyte counts in splenectomized Apoe-/- mice. The serum cholesterol levels and 
peripheral monocyte counts were determined at 4 wks after vascular injury in 
splenectomized Apoe-/- mice treated with vehicle or CCX771 and fed a HCD (n = 4 to 5 
mice per group). *P < 0.05. 
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3.4 CCX771 treatment reduced diet-induced atherosclerosis 
To investigate the role for CCX771 in diet-induced atherosclerosis, Apoe-/- mice fed a 
HCD were daily treated with CCX771 (10 mg/kg, s.c.) or vehicle (10% Captisol) for 3 
months. To visualize and quantify the extent of atherosclerosis, cross-sections of the 
aortic roots were stained with Movat’s stain and en face prepared aortas were stained with 
oil red O. The size of atherosclerotic lesions in the aortic roots and the relative oil red O-
positive area in the aorta were reduced by CCX771 treatment (Fig. 35), suggesting that 
CCX771 plays a protective role in the development of atherosclerosis.  
 
Figure 35: Effects of CCX771 treatment on diet-induced atherosclerosis in Apoe-/- 
mice. (A) The area of atherosclerotic lesions was quantified by planimetry in Movat- 
stained sections of aortic roots from Apoe-/- mice treated with vehicle or CCX771 after 3 
months on a HCD (n = 10 mice per group). Scale bars, 200 µm; ***P < 0.001 versus 
vehicle treatment. (B) The relative oil red O-stained area was studied in en face prepared 
thoracoabdominal aortas of Apoe-/- mice after treatment with vehicle or CCX771 (n = 10 
mice per group). *P < 0.05 versus vehicle treatment.  
The effects of long-term CCX771 treatment on the cellular composition of 
atherosclerotic lesions were determined by immunostaining of macrophage-specific Mac-
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2 or SMC-specific SM22. The number of Mac-2 immunopositive cells in the lesions was 
reduced by CCX771 treatment compared to vehicle treatment (Fig. 36A). The relative 
SM22 immunopositive area in the lesions of CCX771-treated mice was not significantly 
different from that in vehicle-treated mice (Fig. 36B). These results indicate that CCX771 
treatment reduces the accumulation of macrophages in aortic plaques, whereas the 
lesional SMC content is not affected by CCX771 treatment. 
 
Figure 36. Effects of CCX771 treatment on the cellular composition of aortic root 
lesions in Apoe-/- mice. The number of Mac-2 immunopositive cells (A) and the relative 
SM22 immunopositive area were analyzed in aortic roots of Apoe-/- mice treated with 
vehicle or CCX771 after feeding a HCD for 3 months (n = 10 mice per group). Scale 
bars, 200 µm; **P < 0.01 versus vehicle treatment. 
To investigate whether long-term CCX771 treatment also affects hyperlipidemia 
and hyperlipidemia-induced monocytosis in diet-induced atherosclerosis, lipid levels and 
peripheral monocyte counts were measured in CCX771- or vehicle-treated Apoe-/- mice 
after 3 months of a HCD. The serum cholesterol and triglyceride levels were lower in 
Apoe-/- mice treated with CCX771 than with vehicle (Fig. 37A and 37B). Moreover, the 
peripheral monocyte counts were markedly reduced in mice treated with CCX771 
compared to vehicle (Fig. 37C). However, body weights, creatinine levels, and ALT 
levels were not significantly different between CCX771- and vehicle-treated mice (Fig. 
38). These findings indicate that CCX771 treatment limits monocytosis and severe 
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hypercholesterolemia during diet-induced atherosclerosis in Apoe-/- mice without causing 
relevant hepatic and renal toxicities. 
 
Figure 37. Effects of CCX771 treatment on hyperlipidemia and hyperlipidemia-
induced monocytosis in Apoe-/- mice. The serum cholesterol levels (A), triglyceride 
levels (B), and peripheral monocyte counts (C) were determined in Apoe-/- mice treated 
with vehicle or CCX771 after 3 months of a HCD (n = 9 to 10 mice per group). *P < 0.05 
versus vehicle treatment.  
 
Figure 38. Assessment of CCX771 treatment related toxicities. The body weights (A), 
serum creatinine levels (B), and serum ALT levels (C) were measured in Apoe-/- mice 
treated with vehicle or CCX771 after 3 months on a HCD (n = 10 mice per group). 
 
3.5 Effect of CCX771 treatment cholesterol metabolism 
To study the mechanism of the effects of CCX771 treatment on hyperlipidemia, Apoe-/- 
mice fed a HCD were treated with CCX771 or vehicle for 4 wks and lipoprotein profiles 
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of these mice were assessed by a cholesterol fluorometric assay following fractionation 
by FPLC. The total plasma cholesterol and the VLDL-cholesterol levels, but not the 
LDL-cholesterol and HDL-cholesterol levels were reduced by CCX771 administration 
(Fig. 39), indicating that CCX771 treatment specifically reduces the circulating VLDL-
cholesterol.  
 
Figure 39. Effects of CCX771 treatment on different lipoprotein fractions. (A) Total 
cholesterol levels were measured in uninjured Apoe-/- mice fed a HCD after 4 wks of 
CCX771 or vehicle treatment (n = 5 to 7 mice per group). (B-E) Lipoprotein fractions 
from the plasma of Apoe-/- mice fed a HCD after 4 wks of CCX771 or vehicle treatment 
were separated by FPLC and the cholesterol concentrations in these lipoprotein fractions 
was further determined by a cholesterol fluorometric assay. (B) A representative result of 
the cholesterol concentrations in the different lipoprotein fractions is shown. (C-E) The 
cholesterol concentrations in the VLDL, LDL, and HDL fractions are shown. (n = 5 to 7 
mice per group). *P < 0.05 versus vehicle treatment. 
To study the mechanism underlying the cholesterol-lowering effect of CCX771, 
Apoe-/- mice were treated with CCX771 or vehicle for 4 wks and the uptake of injected 
DiI-labeled VLDL into the visceral adipose tissue (VAT) and liver was analyzed. The 
concentration of DiI was significantly increased in the VAT, but not in the liver of 
CCX771-treated compared to vehicle-treated mice (Fig. 40A). Moreover, cholesterol 
levels were increased in the VAT, but not in the liver from CCX771-treated mice (Fig. 
40B). Accordingly, the DiI fluorescence signal in adipocytes determined by multi-photon 
microscopy in vivo was enhanced in CCX771-treated mice (Fig. 40C). Thus, these data 
indicate that CCX771 administration decreases the blood VLDL levels by enhancing the 
uptake of VLDL to adipose tissue. 
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Figure 40. Effects of CCX771 treatment on the uptake of VLDL to adipose tissues in 
Apoe-/- mice. (A) Uptake of VLDL in the VAT and liver was quantified by measuring the 
DiI fluorescence intensity after injection of DiI-labeled VLDL into Apoe-/- mice fed a 
HCD and treated with vehicle or CCX771 (n = 4 mice per group). (B) Cholesterol levels 
were quantified in the VAT and in the liver of Apoe-/- mice treated with vehicle or 
CCX771 by a cholesterol fluorometric assay (n = 4 mice per group). (C) DiI-labeled 
VLDL (red) was detected in the VAT from Apoe-/- mice treated with vehicle or CCX771 
by multi-photon microscopy (n = 4 mice per group). Scale bars, 100 µm. 
Since VLDL can be internalized by VLDLR or LDLR (157), the mRNA 
expression of Vldlr and Ldlr in the VAT was studied after CCX771 treatment. However, 
CCX771 treatment did not substantially change the Vldlr and Ldlr mRNA expression in 
the VAT (Fig. 41), suggesting that CCX771 treatment promotes internalization of VLDL 
without altering the mRNA expression of Vldlr and Ldlr. 
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Figure 41. Effect of CCX771 on the Vldlr and Ldlr mRNA expression in the VAT. 
The Vldlr and Ldlr mRNA expression levels were determined by qRT-PCR in the VAT 
from Apoe-/- mice fed a HCD and treated with vehicle or CCX771 for 4 wks (n = 3 mice 
per group).  
Furthermore, the mRNA expression and promoter activity of Cxcr7 in VATs were 
investigated by qRT-PCR and X-gal staining in Apoe-/- mice and Cxcr7lacZ/+ mice, 
respectively. In contrast to Cxcr4, the expression of Cxcr7 mRNA in the different VATs 
was as high as in the spleen (Fig. 42A). X-gal positive staining indicating Cxcr7 promoter 
activity was detectable in the vasculature and adipocytes of Cxcr7+/lacZ mice (Fig. 42B). 
Cxcr7+/+ mice served as control for the X-gal staining. Thus, Cxcr7 is highly expressed in 
the endothelium of adipose tissue and in adipocytes.  
  
Figure 42. Expression of Cxcr7 and Cxcr4 in VATs. (A) Expression of Cxcr7 and 
Cxcr4 mRNA was studied in various VATs and spleen (n = 3 mice per group). *P < 0.05 
versus spleen. (B) X-gal staining (Cxcr7 promoter activity) was analyzed in sections of 
VAT from Cxcr7+/lac and Cxcr7+/+ mice (n = 3 mice per group). The rectangle delineated 
by a solid line shows a high magnification view of the area delineated by the dashed 
rectangle. Scale bars, 200 µm. 
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3.6 Endothelial-specific deletion of Cxcr7 and hyperlipidemia 
To study whether the expression of Cxcr7 in ECs plays a role in the regulation of the 
serum cholesterol levels and circulating monocytes, TMX-inducible, endothelial-specific 
Cxcr7 knockout (VE-Cad-Cre+Cxcr7floxApoe-/-) and control mice (VE-Cad-
Cre+Cxcr7WTApoe-/-) were fed a HCD for 4 wks. No significant differences in the serum 
cholesterol levels (Fig. 43A), triglyceride levels (Fig. 43B), and peripheral monocyte 
counts (Fig. 43C) were detectable between TMX-treated VE-Cad-Cre+Cxcr7floxApoe-/- 
and TMX-treated VE-Cad-Cre+Cxcr7WTApoe-/- mice. These findings indicate that the 
expression of Cxcr7 in ECs is not involved in the regulation of hyperlipidemia and 
monocytosis. 
 
Figure 43. Effects of endothelial-specific Cxcr7 deletion on hyperlipidemia and 
hyperlipidemia-induced monocytosis in Apoe-/- mice. The serum cholesterol levels (A), 
triglyceride levels (B), and peripheral monocyte counts (C) in TMX-treated VE-Cad-
Cre+Cxcr7floxApoe-/- and VE-Cad-Cre+Cxcr7WTApoe-/- mice were determined after 4 wks 
of a HCD (n = 8 mice per group). 
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4. DISCUSSION 
4.1 Role of Cxcr7 in vascular repair 
4.1.1. Cxcr7 and neointima formation 
 
The CXCL12/CXCR4 axis modulates vascular remodeling and the development of 
atherosclerosis by orchestrating stem cell mobilization and neutrophils homeostasis, 
respectively (84-88). In contrast to most other chemokines, which bind to various 
receptors, the only known receptor for CXCL12 that mediates its biological effects 
was CXCR4 until the discovery that the orphan receptor RCD1 (now called CXCR7) 
is an alternative receptor for CXCL12 (110, 111). Thus, it needs to be clarified 
whether CXCR7 plays a role in biological processes that were initially attributed only 
to CXCR4. Moreover, CXCR7 may also mediate specific effects of CXCL12 
independently of CXCR4 in atherosclerotic vascular diseases, which have so far not 
been described.  
Either treatment with a Cxcr4 antagonist or a Cxcl12 antibody reduces 
neointima formation following vascular injury (84, 85, 88, 89). However, the role of 
CXCR7 in neointima formation is unclear. In the current study, Cxcr7 deficiency 
exacerbated neointimal hyperplasia after vascular injury in CAG-Cre+Cxcr7floxApoe-/- 
mice. The increased neointima formation was associated with an increased 
accumulation of macrophages, but the relative neointimal SMCs content was not 
altered. Moreover, the effects of Cxcr7 were assessed by using a specific synthetic 
ligand for Cxcr7, CCX771. In contrast to the effects of Cxcr7 deficiency, CCX771 
treatment reduced neointima formation and the macrophage accumulation. Similar to 
the effects of Cxcr7 deficiency, the neointimal SMCs area content was not altered by 
CCX771 treatment. By contrast, either treatment with a Cxcr4 antagonist or a Cxcl12 
antibody decreases the neointimal SMC content and mostly does not affect the 
neointimal macrophage content (84, 85, 87). Only a high dose of the Cxcr4 antagonist 
POL5551 simultaneously decreases neointimal SMC and macrophage contents (89). 
These results indicate that the Cxcl12/Cxcr4 axis plays a more important role in 
neointimal SMC accumulation than in macrophage accumulation. On the other hand, 
Cxcr7 mainly regulated the neointimal macrophage accumulation without affecting 
the relative SMC content. Accordingly, Cxcr7 is involved in the vascular repair after 
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injury, but the underlying mechanisms and effects on neointimal hyperplasia differ 
substantially between Cxcr7 and Cxcl12/Cxcr4.  
4.1.2 Cxcr7 and hyperlipidemia-induced monocytosis  
Apoe-/- mice spontaneously develop atherosclerosis accompanied by hyperlipidemia 
and monocytosis primarily due to an expansion of Ly6C+ monocytes (38, 158, 159). 
High-fat diet feeding further exacerbates the development of atherosclerosis in Apoe-/- 
mice (38, 158-160). During atherosclerosis, the appearance and distribution of 
atherosclerotic lesion in Apoe-/- mice are similar to those observed in humans (160). 
Vascular injury leads to a pronounced neointima formation in Apoe-/- with a B6 
genetic background (161). After denudation of the endothelium, exposure of 
subendothelial components initiates the deposition of platelets and fibrin, leukocyte 
adhesion and infiltration, SMCs proliferation and migration, progenitor mobilization, 
and cytokine release (161). Macrophages and SMCs are the major cellular 
components of the neointima in Apoe-/- mice (161). Similarly, exuberant neointimal 
hyperplasia after coronary stenting in humans is mainly composed of abundant 
macrophages and SMCs (162). Growing evidence supports a crucial role for 
monocytes and lipids in lesion formation and vascular remodeling after vascular 
injury and in the development of atherosclerosis (163-165). In the current study, 
quantification of lipid levels and peripheral monocyte counts demonstrated that 
CCX771 administration reduced the serum cholesterol levels, triglyceride levels, and 
peripheral monocyte counts in Apoe-/- mice while the abrogation of Cxcr7 in CAG-
Cre+Cxcr7floxApoe-/- mice caused the opposite outcome. Deficiency of chemokine 
receptors can cause changes in serum cholesterol levels (166-168). Hyperlipidemia 
leads to monocytosis by promoting monocyte progenitor cell proliferation and 
monocyte survival in animal models (38, 40, 169-171). These findings indicate that 
CCX771 treatment ameliorates hypercholesterolemia and subsequently alleviates 
hypercholesterolemia-induced peripheral monocytosis, whereas Cxcr7 deficiency 
exacerbates hypercholesterolemia and aggravates hypercholesterolemia-induced 
peripheral monocytosis.  
Monocyte subpopulations play a distinct role in different atherosclerotic 
diseases. Swirski et al. reported that Ly6C+ rather than Ly6C- monocytes were 
progressively expanded in an atherosclerosis model in which Apoe-/- mice were fed a 
high-fat diet for 25 wks (38). The expansion of circulating monocytes triggered by 
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elevated cholesterol levels is linked to an improved survival capacity of monocytes 
(38). The same group reported a biphasic monocyte response in a murine model of 
myocardial infarction (35). In phase I, classic monocytes (Ly6C+) dominate at the 
injury sites and are responsible for clearing damaged tissues or cells; in phase II, 
nonclassic monocytes (Ly6C-) monocytes are preferentially recruited to the injury 
site, attenuate inflammation, and promote wound healing (35). Given the 
heterogeneity of monocytes and their divergent functions, the current study further 
tested whether CCX771 differentially regulates the mobilization of the two different 
monocyte subsets. In the current study, the relative proportions of Gr-1high 
(corresponding to Ly6C+) and Gr-1low (corresponding to Ly6C-) monocytes in Apoe-/- 
mice were approximately 65% and 35%, respectively, after 6 d of a HCD. The 
relative proportions of Gr-1high and Gr-1low  monocytes in Apoe-/- mice 4 wks after 
vascular injury were 38% and 62%, respectively. Previous studies reported that the 
relative proportions of Ly6C+ and Ly6C- monocytes in normal C57BL/6 mice were 
about 15% and 85%, respectively (35). Within the first four days after coronary artery 
ligation, the relative values of Ly6C+ and Ly6C- monocytes change to 75% and 25%, 
respectively (35). From day 5 on, the percentage of Ly6C- monocytes increases and 
reaches approximately 85% at day 16 after myocardial infarction (35). The ratio of 
Gr-1high to Gr-1low monocytes was higher in the current study than that in normal 
C57BL/6 mice or after myocardial infarction, which might be due to the 
hypercholesterolemia-induced expansion of Gr-1high monocytes (38). However, 
CCX771 treatment did not affect the ratio of Gr1high to Gr1low monocytes, suggesting 
that Cxcr7 affects hyperlipidemia-induced monocytosis, but not monocyte 
subpopulations.  
Clinical findings demonstrate a correlation between the level of peripheral 
monocytes and vascular diseases. Therefore, monocytosis is considered an 
independent risk factor for atherosclerosis (38, 172-176). In animal models, the 
peripheral monocyte count also correlates with lesional macrophage accumulation, the 
neointimal area, and the size of atherosclerotic lesion (36, 168, 177). Moreover, 
myocardial infarction increases monocyte recruitment and macrophage accumulation, 
accelerating the development and exacerbation of atherosclerosis (178). In addition to 
the SMC migration and proliferation, the neointimal macrophage accumulation is 
positively related to the neointimal area, supporting a decisive role of the macrophage 
accumulation in neointima hyperplasia (179). Accordingly, Cxcr7 might modulate the 
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circulating monocyte counts through regulating the serum cholesterol levels and may 
thereby control the accumulation of neointimal macrophage and neointimal growth. 
4.1.3 Cxcr7 indirectly modulates the macrophages accumulation in neointima 
The results of the current study indicate that Cxcr7 regulates the peripheral monocyte 
counts and the accumulation of macrophages by modulating the serum cholesterol 
levels. However, it remains unclear whether Cxcr7 might affect monocyte 
mobilization and lesional macrophage accumulation by alternative mechanisms.  
A variety of chemokine/chemokine receptor axes act in a sequential, 
independent, and complementary manner to achieve macrophage accumulation in the 
vessels, which is related to the monocyte emigration from the bone marrow to blood, 
monocytosis, monocyte survival, the monocyte adhesion cascade, the differentiation 
from monocytes to macrophages, and the emigration of macrophages from arterial 
plaques (108, 168, 180, 181). For examples, the Cxcl12/Cxcr4 axis can mediate the 
adhesion of monocytes to arteries and affects the neointimal macrophage 
accumulation (88, 89). Moreover, either the absence of CCL2 (monocyte 
chemoattractant protein-1, MCP-1) or the lack of the CCL2 receptor CCR2 decreases 
atherosclerosis and reduces lesional macrophage accumulation (182-184). Ccr2 
deletion leads to an increase of monocytes in the bone marrow, whereas peripheral 
blood monocytes are decreased, suggesting a crucial role for Ccr2 in the emigration of 
monocytes from the bone marrow (185, 186). Ccr2 also promotes monocyte 
recruitment to atherosclerotic lesions, monocyte arrest on platelets, and 
transendothelial migration of monocytes (186-188). Moreover, the homeostasis and 
infiltration of monocytes, particular of the Ly6C+(Gr1+) monocyte subset, is 
dependent on Ccr2 (40, 186). By contrast, Cx3cr1 regulates the monocytosis of the 
Ly6C- monocyte subset (40, 168, 189). In Cx3cr1-/-Apoe-/- mice, reduced 
atherosclerosis due to a decreased lesional macrophage accumulation was observed 
(190). Cx3cr1 can also increase the entrance of both monocyte subsets into plaques 
and promote monocyte survival, suggesting critical functions of Cx3cr1 in the 
development of atherosclerosis (40, 168, 189, 191). Moreover, Ccr5 deficiency 
ameliorates the development of atherosclerotic lesions, which is associated with 
diminished macrophage content, and blocking Ccr5 reduces neointimal hyperplasia 
following vascular injury by reducing macrophage accumulation (192-194). 
Interestingly, combined systemic inhibition of Ccr5, Ccl2, and Cx3cr1 in Apoe-/- mice 
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almost inhibits the development of atherosclerosis and nearly abolishes the arterial 
macrophage accumulation. This markedly reduced arterial macrophage accumulation 
is strongly correlated with a considerable decrease in the peripheral blood monocyte 
counts (168). LDL-derived LPA induces Cxcl1 expression, thereby enhancing 
monocyte adhesion to the vascular endothelium and the accumulation of macrophage 
(88). Furthermore, lack of the Cxcl1 receptor Cxcr2 in bone marrow cells reduces 
atherosclerosis and lowers the lesional macrophage content, which might be due to 
the participation of Cxcl1/Cxcr2 in the integrin-dependent monocyte arrest on ECs 
(166, 195). Additionally, Cx3cr1 is related to the integrin-independent monocytes firm 
adhesion (196, 197). In contrast, Ccr7 dominates the emigration of the monocyte-
derived cells from arterial plaques (198). Considering the intimate relationship 
between chemokine/chemokine receptor axes and the macrophage accumulation, the 
current study explored the participation of Cxcr7 expressed on bone marrow cells in 
the lesional macrophage accumulation.  
Bone marrow is the major organ for the production and storage of monocytes 
(199). However, Cxcr7 deficiency on bone marrow cells did not alter lipid levels, 
peripheral monocyte counts, macrophage accumulation, and neointima formation. 
Moreover, Cxcr7 protein expression was not detectable and Cxcr7 mRNA expression 
was low in the bone marrow and peripheral blood cells, which is consistent with a 
previous study (114). Therefore, Cxcr7 in bone marrow cells, including monocytes, is 
unlikely to play a role in the effects of Cxcr7 on the peripheral monocyte counts. 
The current study showed high Cxcr7 mRNA and protein expression in the 
spleen, which has also been also identified as a monocyte reservoir (156). Splenic 
monocytes, rather than bone marrow monocytes, are initially mobilized to the 
inflamed tissues after injury (156). In line with previous studies, Cxcr7 expression 
was detected in cells of the splenic marginal zone (113, 200). Splenic B cells are 
involved in protective immunity against atherosclerosis (201). However, in the current 
study, removal of the spleen did not affect the effect of CCX771 on the peripheral 
blood monocyte counts and neointima formation, suggesting that splenic Cxcr7 
expression does not affect neointima formation via modulating monocyte 
mobilization.  
CXCL12 mediates the migration and recruitment of monocytes, which 
constitutively express CXCR4 (202, 203). However, no protein expression of Cxcr7 
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was detected on the monocytes, which makes direct effects of Cxcr7 on monocyte 
mobilization highly unlikely. Therefore, the current study provides evidence for an 
indirect role of Cxcr7 on the peripheral monocyte count. 
Moreover, the results of the current study show that Cxcr7 deficiency 
increased the serum cholesterol levels in HCD-fed Apoe-/- mice. However, the serum 
cholesterol levels in mildly hyperlipidemic Cxcr7-/-Apoe+/+ mice were not altered. 
Accordingly, neointima formation and circulating monocyte counts were not changed 
in Cxcr7-/-Apoe+/+ mice, indicating that the effects of Cxcr7 on neointimal hyperplasia 
are dependent on hyperlipidemia. 
Similar to Ccl2-/-Cx3cr1-/-Apoe-/- mice (168), weight gain was not related to the 
alteration of the blood cholesterol levels triggered by Cxcr7 deletion and CCX771 
treatment in the current study. In contrast, Mcsf-/- mice exhibit a lower body weight 
and higher cholesterol levels than those of controls (204). However, the results of the 
current study do not indicate that Cxcr7 deletion or CCX771 treatment regulate 
cholesterol levels through changes in food intake. Moreover, hyperlipidemia not only 
causes monocytosis, but also enhances lipid deposition in the aortic wall, which in 
turn increases monocyte recruitment (205). In conclusion, Cxcr7 indirectly controls 
the macrophage accumulation through modulating the serum cholesterol levels under 
hyperlipidemic conditions without affecting the weight gain. 
4.1.4 Effects of Cxcr7 on SPC mobilization and Cxcl12 levels 
Following mechanical vascular injury, increased plasma Cxcl12 levels trigger the 
mobilization of SPCs (79, 80). Additionally, apoptotic SMCs induce Cxcl12 
expression in medial SMCs, which mobilizes and recruits SPCs to the injury sites (84, 
85, 109). SPCs eventually differentiate into SMCs participating in neointima 
formation (84, 88, 89, 108). Hence, SPCs are one of the major contributing factors in 
neointima formation after mechanical vascular injury (84, 85). Disruption of the 
Cxcl12/Cxcr4 axis reduces neointima formation through inhibiting SPC mobilization 
and recruitment (84, 85, 88, 89). The role of Cxcr7 in this process has not been 
elucidated.  
In the current study, neither Cxcr7 deficiency nor CCX771 treatment 
interfered with SPC mobilization in response to vascular injury, which is consistent 
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with the unchanged neointimal SMC content, suggesting that Cxcr7 is not involved in 
the injury-induced SPC mobilization. 
CXCR7 internalizes and degrades CXCL12 and thereby controls the 
extracellular availability of CXCL12 (134). In the current study, Cxcl12 levels were 
simultaneously elevated in the bone marrow and the circulation of Cxcr7-/- mice and 
after CCX771 treatment. These increased Cxcl12 levels can be explained by 
displacement of Cxcl12 from Cxcr7 by CCX771 and lack of Cxcl12 binding to Cxcr7 
in Cxcr7-/- mice. In both cases, reduced Cxcr7-mediated Cxcl12 internalization may 
impair its degradation and thus increase the Cxcl12 levels.  
In the current study, the elevated circulating Cxcl12 levels did not significantly 
affect SPC mobilization after vascular. This is in contrast to previous studies, which 
demonstrated that increased circulating CXCL12 levels after vascular injury or 
injection of CXCL12 mobilize SPCs (84, 206). However, Cxcr7 deficiency or 
CCX771 treatment also increased CXCL12 in the bone marrow and therefore did not 
change the CXCL12 gradient between the circulation and the bone marrow, which is 
crucial for the retention of stem cells by high CXCL12 levels in the bone marrow (79, 
80, 108). Together, CCX771 treatment or Cxcr7 deficiency did not disrupt the 
gradient of Cxcl12 and therefore increased circulating CXCL12 levels may not 
enhance SPC mobilization after vascular injury.  
4.2 Effects of CCX771 treatment on the development of atherosclerosis 
In the current study, CCX771 treatment after vascular injury decreased blood 
cholesterol levels, which is also a crucial factor in diet-induced atherosclerosis (4). 
Therefore, the effects of long-term CCX771 treatment on diet-induced atherosclerosis 
were further investigated. In line with the effects of CCX771 treatment on neointima 
formation, CCX771 treatment reduced serum cholesterol levels and peripheral 
monocyte counts, limited atherosclerotic lesion formation, and diminished the lesional 
accumulation of macrophages. Moreover, CCX771 treatment did not affect the weight 
gain or impaired hepatic or renal function, suggesting that CCX771 has no major 
hepatic or renal toxicities even after long-term application in mice.  
Furthermore, CCX771 treatment decreased the blood cholesterol levels, 
ameliorated monocytosis, and limited atherosclerotic plaque formation. The protective 
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effects of CCX771 treatment in diet-induced atherosclerosis were identical with its 
effects on neointimal hyperplasia following vascular injury, indicating that CCX771 
acts via similar mechanisms. The effects of Cxcr4 on restenosis and diet-induced 
atherosclerosis are in opposite to those of the treatment with CCX771 (85, 86, 89). 
Cxcr4 promotes restenosis, because blocking Cxcr4 decreases SPC mobilization and 
neointimal SMC accumulation leads to reduced neointimal hyperplasia. Moreover, 
Cxcr4 is protective in diet-induced atherosclerosis, because inhibition of Cxcr4 
induces neutrophilia, which increases atherosclerosis (86). Since the effects of Cxcr4 
and Cxcr7 appear to be largely independent of each other in atherosclerosis and Cxcr7 
appears not, like Cxcr4, to be involved in many important physiological processes 
(85, 86, 207), targeting Cxcr7 might be more favorable for treating restenosis and 
atherosclerotic diseases than interfering with Cxcr4. 
4.3 Effects of CCX771 treatment on the uptake of VLDL into adipose 
tissue 
The blood cholesterol levels is one of the key risk factors that drive the development 
of atherosclerosis (4). Cholesterol alone is insoluble in the blood and is carried by 
different types of lipoproteins in the circulatory system. Lipoproteins are spherical 
complexes with a hydrophobic lipid core that mainly consists of triglycerides and 
cholesterol esters. A hydrophilic shell that contains cholesterol, phospholipids, and 
apoliproteins encloses the lipid core. Apoliproteins serve as cofactors for enzymes and 
are ligands for receptor-mediated processes (208). Lipoproteins can be classified into 
five major classes according to their size, density and composition: chylomicrons 
(CMs), very-low-density lipoproteins (VLDLs), intermediate-density lipoproteins 
(IDLs), low-density lipoproteins (LDLs), and high-density lipoproteins (HDLs). 
Cholesterol is acquired from the diet and is de novo synthesized through the 
mevalonate pathway, which is essentially controlled by the rate-limiting enzyme 3-
hydroxy-3-methlglutaryl coenzyme A (HMG-CoA) (209). Lipoprotein metabolism is 
a network including three major interrelated pathways: the exogenous pathway, the 
endogenous pathway, and the reverse transport pathway. Recent studies showed that 
several cytokines and/or chemokine receptors could regulate serum cholesterol levels 
(166-168, 210). For instance, neither Cx3cr1 nor Ccl2 deficiency in Apoe-/- mice 
changes serum cholesterol levels, whereas simultaneous deletion of Cx3cr1 and Ccl2 
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raises serum cholesterol levels (168). Moreover, transplantation of Cxcr2-/- bone 
marrow in Ldlr-/- mice decreases VLDL-cholesterol levels and reduces lesional 
macrophage accumulation (166). In contrast, transplantation of Ccr5-/- bone marrow 
cells in Ldlr-/- mice or deletion Mcsf in Apoe-/- mice increases cholesterol levels (166). 
Interestingly, transplantation with Ccr5-/- bone marrow reduces macrophage content 
rather than the atherosclerotic plaque size despite the raised cholesterol levels (167). 
Additionally, Mcsf-/-Apoe-/- mice develop smaller atherosclerotic lesion despite higher 
serum cholesterol levels (210).   
High blood cholesterol levels accelerate the deposition of lipids and the 
accumulation of monocytes in lesions, where monocytes differentiate to macrophages 
and thus promote the development of atherosclerotic lesion. These findings strongly 
support a positive correlation between the cholesterol levels and the atherosclerotic 
lesion formation (38, 40, 169-171). The discrepancy between increased cholesterol 
levels and reduced macrophage content following Ccr5 deletion in bone marrow 
could be explained by the double-edged role of Ccr5. Absence of Ccr5 inhibits 
leukocyte migration and enhances an anti-inflammatory immune response, leading to 
the reduced macrophage content (193, 194). On the other hand, elevated cholesterol 
levels in mice with Ccr5 deficient bone marrow promote excessive cholesterol 
deposition into the artery wall and the uptake of cholesterol by macrophages (167). 
These divergent results may explain why Ccr5 abrogation in the bone marrow does 
not affect lesion size. In Mcsf-/-Apoe-/- mice, increased serum cholesterol levels may 
not increase atherosclerosis due to the lack of the differentiation of monocytes to 
macrophages in the absence of macrophage colony-stimulating factor (MCSF) (210). 
Therefore, chemokine receptors can regulate serum cholesterol levels; however, the 
precise mechanism underlying the chemokine-induced regulation of serum cholesterol 
levels remains unclear. 
To study the role of Cxcr7 in lipoprotein metabolism, the effect of CCX771 on 
the lipoprotein profile in Apoe-/- mice was determined in the current study. Treatment 
with CCX771 exclusively decreased the circulating VLDL cholesterol levels in Apoe-
/-
 mice without any effect on the levels of LDL and HDL cholesterol. Of note, the 
lipoprotein profile in Apoe-/- mice is characterized by an elevation of the VLDL/IDL-
derived cholesterol levels, whereas LDL-cholesterol levels are only mildly increased 
and HDL-cholesterol levels are reduced (158, 159). Moreover, triglyceride levels in 
Apoe-/- mice are slightly increased compared with those in wild type mice (158, 159). 
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In the current study, the effect of Cxcr7 on the regulation of VLDL cholesterol levels 
was found only under conditions of elevated VLDL concentrations.  
Statins are one of the preferred first-line drugs in the clinical therapy of 
hypercholesterolemia-related diseases (211). Statins inhibit HMG-CoA reductase to 
lower cholesterol levels, particularly LDL-cholesterol levels, and it also decreases the 
levels of triglycerides, but increases the levels of HDL (212, 213). Anti-atherogenic 
HDL transports cholesterol from peripheral tissues to the liver for excretion and is 
often inversely related to the risk of cardiovascular diseases (214). In comparison to 
statins, CCX771 treatment reduced VLDL and triglyceride levels, without any effect 
on LDL and HDL levels. Additionally, the main target organ for statins is the liver 
(215), where no Cxcr7 protein expression and a remarkably low expression of Cxcr7 
mRNA were observed. This indicates that the mechanism underlying the regulation of 
the cholesterol levels by CCX771 treatment is different from stains. 
Liver is the major organ for the synthesis of VLDL and increased production 
of VLDL in the liver causes familial combined hyperlipidemia (FCH), which is the 
cause for half of all cases of coronary artery disease (216-218). Notably, Cxcr7 
expression was absent in the liver, making the possibility that hepatic Cxcr7 
expression regulates the synthesis of VLDL unlikely. By contrast, abundant Cxcr7 
expression was identified in the spleen, which has been considered to be a site of lipid 
metabolism (154). However, splenectomy did not change the effects of CCX771 
treatment on cholesterol levels. Therefore, the results of the current study suggest that 
splenic Cxcr7 expression is not involved in the regulation of cholesterol levels. 
The current study demonstrated that CCX771 treatment enhances the uptake 
of cholesterol from VLDL into VATs, which may explain the reduced serum VLDL 
levels in CCX771-treated mice. Although Cxcr7 expression was observed in 
adipocytes and ECs of adipose tissue, the uptake of VLDL into adipose tissue is likely 
mediated by the expression of Cxcr7 on adipocytes, because endothelial cell-specific 
Cxcr7 deficiency did not change the serum cholesterol levels. In opposite to the effect 
of CCX771 treatment, absence of Cxcr7 increased serum cholesterol levels indicating 
that activation of Cxcr7 by CCX771 is mediating the lowering of the VLDL levels. In 
contrast to the cholesterol levels, Cxcl12 levels were simultaneously increased in the 
plasma and bone marrow of both Cxcr7-/- and CCX771-treated mice. Therefore, it is 
unlikely that Cxcl12 is directly involved in the uptake of VLDL into adipose tissue 
because the elevated Cxcl12 levels in Cxcr7-/- and CCX771-treated mice cannot 
DISCUSSION 
 
78 
 
explain the oppositional change of the serum cholesterol concentration. However, 
these results support the hypothesis that Cxcr7 regulates the uptake of VLDL into the 
adipose tissue.  
Cxcr7 was highly expressed in VATs, which is not only a primary depot of 
fatty acids stored as triglycerides, but also acts as a large cholesterol reservoir (219). 
Adipocyte is the main cell type in adipose tissue and orchestrate energy metabolism 
and glucose homeostasis (219). In adipocytes, almost all cholesterol exists as free 
unesterified cholesterol due to a lack of acetyl-Coenzyme A acyltransferase (ACAT) 
(220-222). A dynamic cholesterol equilibrium exists between adipose tissues and 
peripheral blood, suggesting a potential buffering effect of adipose tissues against 
hypercholesterolemia (219). Triglyceride-rich lipoproteins (TGRLs), such as CM or 
VLDL, get access to adipocytes from the peripheral blood through passive exchange 
or receptor-mediated endocytosis (219). The latter plays a crucial role in lipoprotein 
metabolism and cholesterol homeostasis (223). For instance, TGRL particles enter 
cells by LDL receptor (LDLr)-mediated endocytosis and are transferred to lysosomes 
where TGRL particles are subsequently degraded to intracellular free fatty acid for de 
novo TG biosynthesis (224). In comparison to LDLr, the VLDLr is abundantly 
expressed in adipose tissue and scarcely detectable in the liver (225-227). VLDLr 
binds to and mediates the internalization of Apoe-containing lipoproteins, such as 
VLDL, IDL and CM (225-227). Following the intracellular accumulation of 
lipoproteins, a negative feedback mechanism including the suppression of HMG-CoA 
and LDLr occurs to stabilize the cellular cholesterol content (228). VLDLr is not part 
of a negative feedback mechanism and is upregulated by peroxisome proliferator-
activated receptor-gamma (PPAR-γ) agonists in adipocytes (229, 230). PPAR-γ is a 
crucial transcription factor for lipid metabolism (229). Accordingly, adipose tissues 
modulate cholesterol homeostasis by orchestrating diverse lipoprotein receptors. In 
the current study, the mRNA expression of Ldlr and Vldlr was not changed by 
CCX771 treatment, suggesting that the enhanced uptake of VLDL into adipocytes 
after CCX771 treatment is not due to the increased transcriptional expression of Ldlr 
and Vldlr. Additionally, β-arrestin-2 increases the endocytosis of LDLr and thus 
ameliorates hypercholesterolemia (231). Therefore, it seems plausible that binding of 
CCX771 to Cxcr7 promotes the uptake of VLDL into adipocytes via β-arrestin-2 
activation (Fig. 44). However, this proposed mechanism remains to be verified.  
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Figure 44. Proposed model of the effects of Cxcr7 on neointima formation and 
atherosclerosis by controlling VLDL metabolism. After ligand binding, activation 
of Cxcr7 in adipocytes promotes the uptake of VLDL into the adipocytes and down-
regulates the serum cholesterol levels. Then, decreased VLDL levels ameliorate 
monocytosis, decrease the lesional macrophage accumulation, and finally reduce 
neointimal hyperplasia and the development of atherosclerosis. 
The current study demonstrated that Cxcr7 deficiency aggravates neointima 
formation, increases peripheral monocyte counts, and elevates cholesterol levels. On 
the contrary, CCX771 administration exerted opposite effects: it reduced neointimal 
hyperplasia and atherosclerotic lesion formation. Thus, CCX771 may serve as an 
agonist that activates Cxcr7, indicating that Cxcr7 is a signaling receptor. Binding of 
CXCL12 to CXCR7 activates the ERK pathway via β-arrestins (117, 131, 133, 232). 
β-arrestins are a family of versatile cytosolic adapter or scaffold proteins controlling 
the signal pathway of seven-transmembrane receptors (233). Either endogenous 
ligand of CXCR7 (CXCL12 or CXCL11) or Cxcr7-specific synthetic ligands (e.g., 
CCX771, CCX733 or CCX754) preferentially recruit β-arrestin to CXCR7 (130, 133, 
234). Additionally, the CXCR4 antagonist AMD3100 also binds to a allosteric site of 
CXCR7 and drives β-arrestins recruitment to CXCR7 (232). CCX771 even enhances 
the CXCL12-mediated β-arrestins recruitment to CXCR7 (133). Therefore, CXCR7 
activates signaling events by recruiting β-arrestin. In contrast, G-protein related 
calcium responses are not triggered by CXCR7 activation, despite it constitutively 
couples to G proteins (125, 126). Additionally, chemotaxis induced by CXCL12 does 
not require CXCR7 (110, 129). In sum, CXCR7 is not directly and functionally 
related to the canonical G protein signaling. 
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CCX771 is a ligand for Cxcr7 with high affinity and specificity (110, 124). In 
the current study, elevated Cxcl12 levels induced by CCX771 treatment combined 
with the opposite results concerning the serum cholesterol levels and monocyte counts 
observed in Cxcr7 deficient mice or CCX771-treated mice indicate that CCX771 can 
act as an agonist of Cxcr7 in vivo. However, CCX771 is generally considered to be an 
antagonist for CXCR7, because it competes with the Cxcr7 ligands CXCL12 and 
CXCL11, and can limit the role of CXCR7 in integrin activation, leukocyte entry into 
the central nervous system, transendothelial migration of tumor cells, and pulmonary 
hypertension (124, 129, 133, 235). These findings are in contrast to the results 
obtained in the current study. One reason for these contradictory results might rely in 
the lack of data from direct inactivation of CXCR7 by genetic deletion or CXCR7 
siRNA treatment in previous studies. Furthermore, the conclusion from the current 
study is supported by the finding that CCX771 recruits β-arrestins with more potency 
than its endogenous ligands leading to an activation of MAP kinases (133). 
Concordantly, two compounds with similar structure as CCX771 have been proven to 
be agonists for Cxcr7 (236, 237). Accordingly, CXCR7 is not just a scavenger 
receptor, and CCX771 might be either an agonist or antagonist in specific 
physiological processes. Treatment with CCX771 might be a promising therapeutic 
approach to treat atherogenic dyslipidemia. 
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5. SUMMARY 
Atherosclerosis is a chronic inflammatory disorder of blood vessels and is 
orchestrated by diverse cytokines, lipoproteins, blood cells, and cellular elements of 
the arterial wall (3, 4). Chemokine/chemokine receptor axes play a crucial role in the 
pathogenesis of atherosclerotic vascular diseases. The CXCL12/CXCR4 axis plays a 
fundamental role in vascular remodeling and the development of atherosclerosis. 
Most of these effects of CXCL12 have been linked to the interaction with CXCR4. 
However, the function of the alternative CXCL12 receptor, CXCR7, in the 
development of atherosclerosis and vascular remodeling remains elusive. 
The results of the current study show that the loss of Cxcr7 expression in 
Apoe-/- mice enhanced neointima formation after vascular injury. Increased neointimal 
hyperplasia in the absence of Cxcr7 is associated with increased macrophage 
accumulation in the neointima. The latter effect can be attributed to elevated serum 
cholesterol and triglyceride levels, which may promote hyperlipidemia-induced 
monocytosis. However, Cxcr7 deficiency did not alter the SPC mobilization after 
vascular injury, suggesting that the Cxcl12 gradient still exists due to the finding that 
the levels of this chemokine in the bone marrow and blood are simultaneously 
elevated. Unlike Cxcr7 deficiency in Apoe-/- mice, Cxcr7 deficiency in Apoe+/+ mice 
fed a HCD did not exacerbate neointima formation or affect lipid levels and 
monocytosis after vascular injury, indicating that hyperlipidemia is required for the 
effects of Cxcr7 on neointima formation. Moreover, deficiency of Cxcr7 only in bone 
marrow cells had no effect on neointima formation, which makes a role of Cxcr7 on 
leukocytes in lesion formation unlikely.  
In contrast to the effect of Cxcr7 deficiency, administration of the Cxcr7 
ligand CCX771 in Apoe-/- mice inhibited neointima formation. In addition, CCX771 
reduced cholesterol and triglyceride levels, and diminished monocytosis. Moreover, 
removal of spleen did not reverse the effects of CCX771 on neointima formation, 
excluding an important role of splenic Cxcr7 expression in neointima formation. 
Given the cholesterol-lowing effect of CCX771, this study further investigated the 
effect of CCX771 in diet-induced atherosclerosis and found that CCX771 treatment 
ameliorated lesion formation and hyperlipidemia in diet-induced atherosclerosis. Of 
note, CCX771 treatment did not result in any obvious toxicity. Lipid profiling 
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analysis further demonstrated that CCX771 treatment preferentially down-regulates 
VLDL levels without affecting LDL and HDL levels.  
This study showed that CCX771 treatment increased the cholesterol levels and 
the uptake of VLDL into adipocytes. However, CCX771 treatment did not alter the 
cholesterol levels and the uptake of VLDL in the liver. Moreover, endothelial-specific 
Cxcr7 deficiency failed to increase the cholesterol levels and promote monoytosis. 
Therefore, the reduced circulating VLDL levels by CCX771 treatment could be 
attributable to the increased uptake of VLDL into Cxcr7-expressing adipocytes. Thus, 
the data of the current study indicate that Cxcr7 regulates blood cholesterol levels by 
promoting its storage in adipocytes.  
In conclusion, this study suggests a key role of Cxcr7 in controlling vascular 
neointima formation and the development of atherosclerosis. Cxcr7 activation 
promotes the uptake of VLDL into adipose tissues and decreases the blood cholesterol 
levels, especially VLDL cholesterol levels. As a consequence, Cxcr7 activation 
ameliorates hyperlipidemia and hyperlipidemia-induced monocytosis. The combined 
down regulation of cholesterol levels and peripheral monocyte counts might not only 
cause a reduction in the number of monocytes entering into vascular wall, but also 
reduce the differentiation from monocytes to macrophages. Reduced accumulation of 
macrophages may reduce the progression of neointimal hyperplasia and the formation 
of atherosclerotic plaques. CCX771, a Cxcr7 ligand, could potentiate the athero-
protective effects of Cxcr7. Accordingly, this unexpected cholesterol-lowering effect 
of Cxcr7 may be beneficial in atherosclerotic vascular diseases and can be 
therapeutically augmented using a synthetic Cxcr7 ligand, CCX771. 
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